Phospholipid Compounds and Formulations

The development of phospholipid compounds for microspheres addresses the need for safe and effective treatments of obstructive masses by enabling large-scale production of high-quality microspheres for therapeutic use, particularly in treating urolithiasis with minimal invasive procedures.

JP7587868B2Active Publication Date: 2024-11-21AVIO MEDICAL INC
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2022571732
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2020-01-28
Publication Date
2024-11-21
Estimated Expiration
2040-01-28

AI Technical Summary

Technical Problem

There is a need for improved phospholipid compounds that are safe and therapeutically effective for medical applications, particularly for the treatment of abnormal or obstructive masses such as kidney stones, and that can be manufactured in large quantities with high quality for commercial use.

Method used

The development of phospholipid compounds, including Formula IV, Formula I, and Formula III, which are used to create microspheres with a fluid core and lipid shell, capable of forming microspheres with specific molecular weights and ratios, and are produced through a method involving blending, homogenizing, and lyophilizing to achieve therapeutic and commercial use.

Benefits of technology

The described phospholipid compounds enable the production of high-quality microspheres on a large scale, which can be administered to treat conditions like urolithiasis with minimal invasive procedures, reducing the need for surgical interventions and improving patient outcomes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007587868000076
    Figure 0007587868000076
  • Figure 0007587868000077
    Figure 0007587868000077
  • Figure 0007587868000078
    Figure 0007587868000078
Patent Text Reader

Abstract

The present disclosure provides phospholipid-containing compounds, pharmaceutical compositions, and microspheres that exhibit high affinity for mineralized metals. The present disclosure also provides strategies for using the compounds, compositions, and microspheres in the treatment of nephrolithiasis or kidney stone disease, as well as methods for manufacturing and preparing the compounds and compositions. The present disclosure provides compounds, pharmaceutical compositions, and microsphere particles (or microspheres or particles) that exhibit high affinity for calcium and other metals in mineralized forms, including hydrophobic and biomineralized forms.
Need to check novelty before this filing date? Find Prior Art

Description

[Background technology]

[0001] 2. Background of the Invention Microspheres, which have a fluid core surrounded by a thin shell composed of lipids, proteins and / or sugars, are used in medical and therapeutic products. These micron-scale gas-core particles, sometimes called microparticles, have been administered systemically to increase the information content of echocardiograms. Microspheres may be particularly useful in opacifying the left ventricle of the heart, allowing echocardiograms to more accurately reveal details of aortic valve surgery. A category of microsphere products designed to be used in disease diagnosis in this way are often called ultrasound contrast agents (UCAs). The use of UCAs utilizes a mechanical energy source (e.g., ultrasound to generate echocardiograms) and although an associated microsphere mechanical response always occurs, they typically do not rely on tissue effects from the microsphere's mechanical response for their function, and in fact are often designed to minimize tissue effects.

[0002] Microspheres can also be used in treatments where the mechanical response of the microspheres is central, with either direct or indirect associated tissue effects. For example, it has been suggested that for certain cancers, microspheres can be used for targeted delivery of chemotherapeutic agents. For targeted delivery, microsphere design generally requires the combination of tumor-specific ligands in the shell structure and liquid-phase chemotherapeutic agents in the core. After administration, the tumor-specific ligands in the shell are expected to cause the microspheres to accumulate in and around the tumor. A mechanical energy source can then be used to disrupt the microspheres and release the chemotherapeutic agents from the core.

[0003] The mechanical action of microspheres can also be used in the treatment of pathological biomineralization, as described in U.S. Patent Application Publication No. 2013 / 0123781, which is incorporated herein by reference in its entirety. In these treatments, microspheres are designed to produce pressure effects similar to those of shock wave lithotripsy, where powerful shock waves are focused on kidney or ureteral stones. In shock wave lithotripsy, focused high-intensity pressure waves with peak pressures exceeding 100 megapascals result in a cavitational action that gradually erodes, punctures, and fragments the stone. In microsphere-based lithotripsy, the microspheres that accumulate on the stone surface can exhibit cavitational action at pressures similar to or exceeding those of conventional shock wave lithotripsy, but with input mechanical energy as much as two orders of magnitude lower (Pishchalnikov et al., 2018). Compared to conventional shock wave lithotripsy, the less intense input acoustic energy can have various advantages in terms of both clinical workflow and patient outcomes. Microsphere accumulation on the stone surface can be enhanced by incorporating bisphosphonate-like moieties into the microsphere shell.

[0004] The mechanical action of the microspheres can be used to treat a variety of medical conditions involving abnormal or obstructive masses such as kidney stones, urinary stones, bile duct stones, blood clots, fibroids, cancerous tumors, and atherosclerotic plaques. This treatment method allows for minimally invasive treatment of medical conditions by destroying or reducing the masses without damaging healthy tissue, minimizing the pain, discomfort, and risks associated with surgical or other invasive procedures. Considering the wide range of therapeutic applications of microspheres, efforts have been made to develop improved components for therapeutic microspheres.Despite these efforts, there is still a need in the art for improved safe and therapeutically effective phospholipid compounds.In addition, it is important to develop phospholipid compounds that can be produced in large quantities and with high quality for therapeutic and commercial use of therapeutic microspheres. [Prior art documents] [Patent documents]

[0005] [Patent Document 1] US Patent Application Publication No. 2013 / 0123781 Summary of the Invention [Means for solving the problem]

[0006] overview The present disclosure provides compounds, pharmaceutical compositions and microsphere particles (or microspheres or particles) that exhibit hydrophobicity and high affinity for calcium and other metals in mineralized form, including biomineralization. The present disclosure further provides methods for making and preparing the compounds, compositions and microsphere particles, and methods for using them to treat medical conditions involving abnormal or obstructive masses, such as nephrolithiasis or kidney stone disease. The methods described herein allow for the production of high quality microspheres on a large scale, enabling therapeutic and commercial use of therapeutic microspheres.

[0007] Thus, in a first aspect, the present disclosure provides a compound of formula IV [ka] Formula IV or a salt, isomer or salt of an isomer thereof, wherein p is 10 to 30; q is 1 to 100; C is [ka] is selected from the group consisting of B is selected from the group consisting of a covalent bond and an ethyl group; A is selected from the group consisting of a covalent bond, acyl, acylamino, aminoacyl, acyloxy, thioacyl, aminocarbonyl, aminoacylcarbonyloxy, aminothiocarbonyl, aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy, aminosulfonyloxy, aminosulfonylamino, aminosulfonyl, amidino, and a carboxy ester; X is hydrogen, silyl, acyl, aminoacyl, thioacyl, aminocarbonyl, aminoacylcarbonyloxy, aminothiocarbonyl, aminosulfonyl, amidino, substituted sulfonyl, substituted sulfinyl, carboxy ester, phthalimide, SO 3 H and PO 3 H.

[0008] In some embodiments, p is 14 or 16 and q is 38-50.

[0009] In some embodiments, the compound of formula IV is a compound of formula I [ka] or a salt, isomer or salt of an isomer thereof, wherein n is 10 to 30; m is 1 to 100.

[0010] In some embodiments, n is 14 or 16 and m is 38-50.

[0011] In some embodiments, the compound of formula I is a compound of formula Ia [ka] or a salt, isomer or salt of an isomer thereof.

[0012] In some embodiments, the compound of formula I is represented by formula Ib [ka] It is a compound of the formula:

[0013] In a second aspect, the present disclosure provides a compound of formula IV [ka] or a pharma- ceutically acceptable salt, isomer or salt of the isomer thereof, During the ceremony, p is 10 to 30; q is 1 to 100; C is [ka] is selected from the group consisting of B is selected from the group consisting of a covalent bond and an ethyl group; A is selected from the group consisting of a covalent bond, acyl, acylamino, aminoacyl, acyloxy, thioacyl, aminocarbonyl, aminoacylcarbonyloxy, aminothiocarbonyl, aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy, aminosulfonyloxy, aminosulfonylamino, aminosulfonyl, amidino, amido, and carboxy ester; X is hydrogen, silyl, acyl, aminoacyl, thioacyl, aminocarbonyl, aminoacylcarbonyloxy, aminothiocarbonyl, aminosulfonyl, amidino, substituted sulfonyl, substituted sulfinyl, carboxy ester, phthalimide, OH SO 3 H and PO 3 H.

[0014] In some embodiments, p is 14 or 16 and q is 38-50.

[0015] In some embodiments, the composition further comprises: Compound of Formula II [ka] or a pharma- ceutically acceptable salt, isomer, or salt of an isomer thereof; Compound of Formula III [ka] or a pharma- ceutically acceptable salt, isomer, or salt of an isomer thereof; During the ceremony, t is between 10 and 30; y is 1 to 100; z is between 10 and 30.

[0016] In some embodiments, t is 14 or 16, z is 14 or 16, and y is 38-50.

[0017] In some embodiments, the compound of formula IV is a compound of formula I [ka] or a pharma- ceutically acceptable salt, isomer, or salt of an isomer thereof, n is 10 to 30; m is 1 to 100.

[0018] In some embodiments, n is 14 or 16 and m is 38-50.

[0019] In some embodiments, the compound of formula I is a compound of formula Ia [ka] or a pharma- ceutically acceptable salt, isomer, or salt of an isomer thereof.

[0020] In some embodiments, the compound of formula Ia has formula Ib [ka] It is a compound of the formula:

[0021] In some embodiments, the composition further comprises a fluid having a normal boiling point of less than 30° C., and optionally at least one pharma- ceutically acceptable excipient. In some embodiments, the fluid is a gas at body temperature. In some embodiments, the fluid has low solubility in aqueous solutions. In some embodiments, the fluid is air, nitrogen, argon, carbon dioxide (CO 2 ), sulfur hexafluoride, C fluoride 1~6 In some embodiments, the fluorinated C 1~6 The alkane is selected from octafluoropropane, n-decafluorobutane and dodecafluoropentane.

[0022] In some embodiments, the composition comprises 0.01-5 mol% of a compound of formula IV or formula I, or a salt, isomer, or salt of an isomer thereof. In some embodiments, the composition comprises 5-9.9 mol% of a compound of formula II, or a salt, isomer, or salt of an isomer thereof. In some embodiments, the composition comprises 80-95 mol% of a compound of formula III, or a salt, isomer, or salt of an isomer thereof. In some embodiments, the composition comprises 5 mol% or less of a compound of formula IV or formula I, or a salt, isomer, or salt of an isomer thereof. In some embodiments, the composition comprises 10 mol% or less of a compound of formula II, or a salt, isomer, or salt of an isomer thereof. In some embodiments, the composition comprises 95 mol% or less of a compound of formula III, or a salt, isomer, or salt of an isomer thereof.

[0023] In some embodiments, the composition comprises an ammonium salt of a compound of formula IV or formula I. In some embodiments, the composition comprises an ammonium salt of a compound of formula II.

[0024] In some embodiments, the molecular weight of the compound of formula IV or formula I is 1,500-5,000 daltons. In some embodiments, the molecular weight of the compound of formula II is 1,500-5,000 daltons. In some embodiments, the molecular weight of the compound of formula III is 500-2,000 daltons.

[0025] In some embodiments, the molar ratio of the compound of formula IV or formula I to the compound of formula II ranges from 1:100 to 1: 1. In some embodiments, the molar ratio of the compound of formula II to the compound of formula III ranges from 1:20 to 1:8.

[0026] In some embodiments, the compound of formula Ia is a compound of formula Ib [ka] and The compound of formula II is a compound of formula IIb [ka] and The compound of formula III is a compound of formula IIIa [ka] and The composition includes a fluid, the fluid being n-decafluorobutane.

[0027] In some embodiments, the average molecular weight of the compound of formula Ib is about 3200 Daltons. In some embodiments, the average molecular weight of the compound of formula IIb is about 2800 Daltons. In some embodiments, the average molecular weight of the compound of formula IIIa is about 790 Daltons.

[0028] In some embodiments, the composition comprises 0.01-5 mol% of a compound of formula Ib. In some embodiments, the composition comprises 5-9.9 mol% of a compound of formula IIb. In some embodiments, the composition comprises 80-95 mol% of a compound of formula IIIa. In some embodiments, the composition comprises 5 mol% or less of a compound of formula Ib. In some embodiments, the composition comprises 10 mol% or less of a compound of formula IIb. In some embodiments, the composition comprises 95 mol% or less of a compound of formula IIIa.

[0029] In some embodiments, the molar ratio of the compound of formula Ib to the compound of formula IIb ranges from 1:100 to 1: 1. In some embodiments, the molar ratio of the compound of formula IIb to the compound of formula IIIa ranges from 1:20 to 1:8.

[0030] In some embodiments, the composition can form a microsphere in the presence of water. In some embodiments, the composition comprises a microsphere. In some embodiments, the microsphere comprises a compound of formula Ib, a compound of formula IIb, and a compound of formula IIIa.

[0031] In some embodiments, the microspheres have an average diameter of about 0.5 microns to about 10 microns, hi some embodiments, the microspheres have an average diameter of about 1 micron to about 5 microns.

[0032] In some embodiments, the composition comprises trehalose and PLASDONE K12 as excipients. In some embodiments, the composition comprises microspheres that are present as a lyophilized dry powder or a water-free concentrate.

[0033] In another aspect, the present disclosure provides a method of producing a microsphere, the method comprising: (a) Below: Compounds of Formula I [ka] or a salt thereof, an isomer thereof, or a salt thereof, Compound of Formula II [ka] or a salt thereof, an isomer thereof, or a salt thereof, Compound of Formula III [ka] or a salt thereof, an isomer thereof, or a salt thereof, Optionally, at least one pharma- ceutically acceptable excipient, and water preparing a formulation for making microspheres comprising: During the ceremony, n is 10 to 30; m is 1 to 100; t is between 10 and 30; y is 1 to 100; z is 10 to 30; X is hydrogen, silyl, acyl, aminoacyl, thioacyl, aminocarbonyl, aminoacylcarbonyloxy, aminothiocarbonyl, aminosulfonyl, amidino, substituted sulfonyl, substituted sulfinyl, carboxy ester, phthalimide, OH, SO 3 H and PO 3 H.

[0034] In some embodiments, the method further comprises: (b) combining the formulation of step (a) with a fluid having a normal boiling point of less than 30° C. in a container; (c) agitating the vessel containing the formulation and fluid from step (b), thereby obtaining microspheres. Includes.

[0035] In some embodiments, the method further comprises: (d) treating the microsphere solution from step (c) to extend its shelf life or to expand the range of environmental conditions for storage. Includes.

[0036] In some embodiments, the method further comprises: (e) stoppering the container containing the microspheres from step (c) or (d), optionally under vacuum. Includes.

[0037] In some embodiments, the formulation of step (a) is filtered prior to step (b). In some embodiments, the processing step (d) is lyophilizing the microsphere solution.

[0038] In some embodiments, the container is a unit dose container. In some embodiments, the fluid is n-decafluorobutane. In some embodiments, the headspace of the capped container is filled with n-decafluorobutane.

[0039] In some embodiments, the average diameter of the microspheres from step (c) is about 0.1-1000 μm. In some embodiments, the average diameter of the microspheres from step (c) is about 0.1-100 μm. In some embodiments, the average diameter of the microspheres from step (c) is about 0.1-30 μm. In some embodiments, the average diameter of the microspheres from step (c) is about 0.7-10 μm.

[0040] In some embodiments, the processing step (d) is freeze-drying the microsphere solution, and the loss of microspheres during freeze-drying is 25% or less, hi some embodiments, the loss of microspheres during freeze-drying is 15% or less, or 10% or less.

[0041] In some embodiments, the molecular weight of the compound of formula I is 1,500-5,000 daltons. In some embodiments, the molecular weight of the compound of formula II is 1,500-5,000 daltons. In some embodiments, the molecular weight of the compound of formula III is 500-2,000 daltons.

[0042] In some embodiments, the molar ratio of the compound of formula I to the compound of formula II in the formulation ranges from 1:100 to 1: 1. In some embodiments, the molar ratio of the compound of formula II to the compound of formula III in the formulation ranges from 1:20 to 1:8.

[0043] In some embodiments, the microspheres from step (c) comprise 0.01-5 mol% of the compound of formula I. In some embodiments, the microspheres from step (c) comprise 5-9.9 mol% of the compound of formula II. In some embodiments, the microspheres from step (c) comprise 80-95 mol% of the compound of formula III. In some embodiments, the microspheres from step (c) comprise 5 mol% or less of the compound of formula I. In some embodiments, the microspheres from step (c) comprise 10 mol% or less of the compound of formula II. In some embodiments, the microspheres from step (c) comprise 95 mol% or less of the compound of formula III.

[0044] In some embodiments, the compound of formula I is a compound of formula Ib, the compound of formula II is a compound of formula IIb, and the compound of formula III is a compound of formula IIIa.

[0045] In some embodiments, the average molecular weight of the compound of formula Ib is about 3200 Daltons. In some embodiments, the average molecular weight of the compound of formula IIb is about 2800 Daltons. In some embodiments, the average molecular weight of the compound of formula IIIa is about 790 Daltons.

[0046] In some embodiments, the microspheres from step (c) comprise 0.01-5 mol% of the compound of formula Ib. In some embodiments, the microspheres from step (c) comprise 5-9.9 mol% of the compound of formula IIb. In some embodiments, the microspheres from step (c) comprise 80-95 mol% of the compound of formula IIa.

[0047] In some embodiments, the microspheres from step (c) contain 5 mol% or less of the compound of formula Ib. In some embodiments, the microspheres from step (c) contain 10 mol% or less of the compound of formula IIb. In some embodiments, the microspheres from step (c) contain 95 mol% or less of the compound of formula IIIa.

[0048] In some embodiments, the molar ratio of the compound of formula Ib to the compound of formula IIb in the microspheres from step (c) ranges from 1:100 to 1: 1. In some embodiments, the molar ratio of the compound of formula IIb to the compound of formula IIIa in the microspheres from step (c) ranges from 1:20 to 1:8.

[0049] In yet another aspect, the disclosure provides a unit dosage container comprising a therapeutically effective amount of the pharmaceutical composition provided herein. In some embodiments, the compound of formula I is a compound of formula Ib. In some embodiments, the compound of formula II is a compound of formula IIb. In some embodiments, the compound of formula III is a compound of formula IIa. In some embodiments, the fluid is air, CO 2 , sulfur hexafluoride, C fluoride 1~6 In some embodiments, the fluorinated C 1~6 The alkane is selected from octafluoropropane, n-decafluorobutane, and dodecafluoropentane. In some embodiments, the fluid is n-decafluorobutane. In some embodiments, the composition comprises trehalose and PLASDONE K12 as excipients. In some embodiments, the composition further comprises a buffer, the buffer being a phosphate. In some embodiments, the buffer comprises calcium and magnesium free saline.

[0050] In some embodiments, the composition can form microspheres in the presence of water. In some embodiments, the composition comprises microspheres. In some embodiments, the microspheres are present as a lyophilized dry powder or a water-free concentrate. In some embodiments, the container is prepared by the process provided herein. In some embodiments, the container is sealed by a crimp-top cap fitted with a septum. In some embodiments, the container is airtight.

[0051] In one embodiment, the present disclosure provides a kit comprising at least one unit dosage container as described above and instructions for using said kit.

[0052] In some embodiments, the unit dose container comprises trehalose and PLASDONE K12 as excipients. In some embodiments, the kit further comprises a container comprising an aqueous solution. In some embodiments, the aqueous solution is sterile water. In some embodiments, the aqueous solution is a saline solution ready for irrigation. In some embodiments, the kit further comprises a syringe. In some embodiments, the kit further comprises a needle adapted for use with the syringe. In some embodiments, the kit comprises a needleless syringe comprising a sharp tip. In some embodiments, the needle or sharp tip is capable of penetrating a septum cap.

[0053] In some embodiments, the kit further comprises a container containing a fluid having a normal boiling point of less than 30° C., and optionally the container is a syringe. In some embodiments, the fluid is air, nitrogen, argon, CO 2 , sulfur hexafluoride, C fluoride 1~6 In some embodiments, the fluorinated C 1~6 The alkane is selected from octafluoropropane, n-decafluorobutane, and dodecafluoropentane, hi some embodiments, the fluid is n-decafluorobutane.

[0054] In some embodiments, the kit further comprises at least one gel pad and ultrasound gel. In some embodiments, the kit further comprises a device selected from a Mix2Vial® device and a vented vial adapter.

[0055] Another aspect of the present disclosure provides a method of reconstituting a microsphere, the method comprising: (a) adding a sufficient amount of water or saline solution to the microspheres in a container of the present disclosure; (b) optionally adding a volume of a fluid having a normal boiling point of less than 30° C. to the vessel of step (a); (c) optionally shaking the vessel of step (a) or step (b); Includes.

[0056] In some embodiments, the method further comprises charging the container with gas prior to step (a). In some embodiments, the amount of water or saline solution is 100 milliliters or less. In some embodiments, the amount of water or saline solution added is sufficient to produce a homogenous mixture containing reconstituted microspheres. In some embodiments, the shaking of the container lasts for 180 seconds or less.

[0057] In yet another aspect, the present disclosure provides a method of treating urolithiasis, the method comprising administering to a subject having urolithiasis an effective amount of a pharmaceutical composition, microspheres or reconstituted microsphere solution disclosed herein, causing the microspheres to contact the urinary stone, and directionally applying energy to the urinary stone in the subject at a frequency that excites fluid within the microsphere.

[0058] In some embodiments, the reconstituted microsphere solution is administered to the subject's ureter through a urinary catheter. In some embodiments, the energy is electromagnetic, acoustic, microwave, photonic, or other form. In some embodiments, the energy is ultrasound.

[0059] In some embodiments, the ultrasonic energy is in the frequency range of 100 kilohertz (kHz) to 2 megahertz (MHz). In some embodiments, the ultrasonic energy is associated with a peak pressure in the range of 0.1 MPa to 10 MPa. In some embodiments, the energy is applied for an amount of time sufficient to fragment the urinary stones.

[0060] In some embodiments, the amount of time is 100 minutes or less. In some embodiments, the amount of time is 90 minutes or less. In some embodiments, the amount of time is 80 minutes or less. In some embodiments, the amount of time is 70 minutes or less. In some embodiments, the amount of time is 60 minutes or less. In some embodiments, the amount of time is 50 minutes or less. In some embodiments, the amount of time is 40 minutes or less. In some embodiments, the amount of time is 30 minutes or less. In some embodiments, the amount of time is 25 minutes or less. In some embodiments, the amount of time is 20 minutes or less. In some embodiments, the amount of time is 15 minutes or less. In some embodiments, the amount of time is 10 minutes or less.

[0061] In some embodiments, the applied energy causes a change in the volume of the reconstituted microspheres or other cavitation effects on the microspheres. In some embodiments, the cavitation of the microspheres causes a pressure gradient change and other mechanical effects on the urinary stone around the reconstituted microspheres. In some embodiments, the pressure gradient change and other mechanical effects can fragment the urinary stone. In some embodiments, the subject is a human.

[0062] In one aspect, the present disclosure provides a reconstituted microsphere solution for use in the treatment of urolithiasis, comprising administering to a subject an effective amount of said microsphere solution so as to contact the microparticles with the urinary stones, and applying energy in a directionally directed manner to the urinary stones in the subject at a frequency that excites the fluid within the microspheres.

[0063] In some embodiments, the reconstituted microsphere solution is administered to the subject's ureter through a urinary catheter. In some embodiments, the energy is electromagnetic, acoustic, microwave, photonic, laser, or other form. In some embodiments, the energy is ultrasound.

[0064] In some embodiments, the ultrasonic energy is in the frequency range of 100 kilohertz (kHz) to 2 megahertz (MHz). In some embodiments, the ultrasonic energy is associated with a peak pressure in the range of 0.1 MPa to 10 MPa.

[0065] In some embodiments, the energy is in the form of a laser. In some embodiments, the laser energy has a wavelength in the infrared range of 1000 nm to 2500 nm. In some embodiments, the laser energy can vaporize the intraluminal liquid, thereby generating associated acoustic waves. In some embodiments, the laser energy has a frequency in the range of 1 kHz to 1 MHz.

[0066] In some embodiments, the energy is applied for an amount of time sufficient to fragment the urinary stone. In some embodiments, the amount of time is 100 minutes or less. In some embodiments, the amount of time is 90 minutes or less. In some embodiments, the amount of time is 80 minutes or less. In some embodiments, the amount of time is 70 minutes or less. In some embodiments, the amount of time is 60 minutes or less. In some embodiments, the amount of time is 50 minutes or less. In some embodiments, the amount of time is 40 minutes or less. In some embodiments, the amount of time is 30 minutes or less. In some embodiments, the amount of time is 25 minutes or less. In some embodiments, the amount of time is 20 minutes or less. In some embodiments, the amount of time is 15 minutes or less. In some embodiments, the amount of time is 10 minutes or less.

[0067] In some embodiments, the applied energy causes a change in the volume of the reconstituted microspheres or other cavitational effects on the microspheres. In some embodiments, the cavitation of the microspheres causes pressure gradient changes and other mechanical effects on the urine around the reconstituted microspheres. In some embodiments, the pressure gradient changes and other mechanical effects can fragment urinary stones. In some embodiments, the subject is a human.

[0068] These and other features, aspects, and advantages of the present invention will become better understood with regard to the following description and accompanying drawings. [Brief description of the drawings]

[0069] [Figure 1] FIG. 1 shows a cut-away schematic of an exemplary microsphere attached to a mineralized material 105, including a microsphere shell component 120 that promotes accumulation, a microsphere lipid shell 110, and a microsphere fluid core 115.

[0070] [Diagram 2] FIG. 2 is a block diagram showing exemplary steps for synthesizing bisphosphonate-PEG-lipids provided in the present disclosure.

[0071] [Diagram 3] FIG. 3 is a block diagram showing exemplary steps for preparing bisphosphonate-PEG-lipids to produce microspheres provided in the present disclosure.

[0072] [Figure 4] FIG. 4 shows the liquid phase size distribution of bisphosphonate-PEG-lipid mixtures measured by dynamic light scattering (DLS).

[0073] [Diagram 5] FIG. 5 shows samples of a bisphosphonate-PEG-lipid composition with a gas headspace (left) and a microsphere formulation of a composition described herein (right), illustrating the qualitative differences between the two formulations.

[0074] [Figure 6] 6 is a graph showing the results of a microsphere accumulation assay over time, which shows that microspheres incorporating the disclosed bisphosphonate-PEG-lipids have a higher rate of microsphere accumulation on the mineralized surface compared to microspheres lacking the bisphosphonate-PEG-lipids in the shell.

[0075] [Figure 7] Figure 7 shows the size distribution of microspheres measured by electrozone sensing. The number of particles (y-axis) in each bin of diameter (x-axis) is provided.

[0076] [Figure 8] FIG. 8 shows the 1H-NMR spectrum of intermediate PEG2DA.

[0077] [Figure 9] FIG. 9 shows the 1H-NMR spectrum of the intermediate 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DSPE-PEG2)-COOH.

[0078] [Figure 10] FIG. 10 shows the 31P-NMR spectrum of the intermediate 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DSPE-PEG2)-COOH.

[0079] [Figure 11] FIG. 11 shows the 1H-NMR spectrum of the compound of formula Ib.

[0080] [Figure 12] FIG. 12 shows the 31P-NMR spectrum of the compound of formula Ib.

[0081] [Figure 13] FIG. 13 shows a gas chromatograph of the headspace analysis of n-decafluorobutane.

[0082] [Figure 14]FIG. 14 shows the 31P-NMR spectrum of a liposome formulation containing the compound of formula Ib, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (ammonium salt) (DSPE-PEG2K, compound of formula IIb) and 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC, compound of formula IIIa). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0083] Detailed Description of the Invention definition Unless otherwise defined herein, all technical and scientific terms used herein have the meaning commonly understood by one of ordinary skill in the art to which this invention belongs.

[0084] The term "subject" refers to any mammal, including humans, as well as mammals such as animals of veterinary and research interest, including, but not limited to, monkeys, cows, horses, dogs, cats, and rodents.

[0085] The term "treating" a disorder or disease or "treatment" of a disorder or disease refers to taking steps to alleviate the symptoms of the disorder or disease, for example, reducing, destroying or removing abnormal or obstructive masses such as kidney stones, urinary stones, bile duct stones, blood clots, fibroids, cancerous tumors and adenoid plaques, or otherwise obtain some beneficial or desired result for a subject, including a clinical result. Any beneficial or desired clinical result may include, but is not limited to, alleviation or amelioration of one or more symptoms of the disorder or disease; reduction in the extent of the disease; delaying or slowing the progression of the disease; amelioration, reduction or stabilization of the disease state; or other beneficial result.

[0086] The term "effective amount" means an amount sufficient to produce a desired effect.

[0087] The term "sufficient amount" means an amount sufficient to produce a desired effect.

[0088] The term "therapeutically effective amount" is an amount effective to ameliorate or reduce symptoms of a disease.

[0089] The term "reduction" of one or more symptoms (and grammatical equivalents of this phrase) refers to a decrease in the severity or frequency of one or more symptoms, or the elimination of one or more symptoms.

[0090] The term "cavitational effect" as used herein refers to an effect sufficient to cause the reduction or destruction of abnormal or obstructive masses in vivo, such as kidney stones, urinary stones, bile duct stones, blood clots, fibroids, cancerous tumors and atheromatous plaques.

[0091] The term "PL2kS" as used herein refers to the compound 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000-alendronate](ammonium salt), which is also disclosed herein as the compound of formula Ib.

[0092] As used herein, the term "DSPE-PEG2K" refers to the compound 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (ammonium salt), which is also disclosed herein as the compound of formula IIb.

[0093] As used herein, the term "DSPC" refers to the compound 1,2-distearoyl-sn-glycero-3-phosphocholine, which is also disclosed herein as the compound of formula IIIa.

[0094] The practice of the present invention involves the use of conventional techniques of organic chemistry, molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry and immunology, which are within the skill of one of ordinary skill in the art.

[0095] In this application, several technical indications will be referred to. All numerical indications (e.g., pH, temperature, time, concentration and weight), including their respective ranges, are approximate values ​​that can typically be varied (+) or (-) by increments of 0.1, 1.0 or 10.0, as appropriate. All numerical indications can be understood as being preceded by the term "about". The reagents described herein are exemplary, and equivalents thereof may be known in the art.

[0096] The compounds utilized in the present invention may possess asymmetric carbon atoms (optical centers) or double bonds. The racemates, diastereomers, geometric isomers, positional isomers and individual isomers (e.g., separate enantiomers) are all intended to be encompassed within the scope of the present invention.

[0097] The compounds of the present invention may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. For example, the compounds may contain radioactive isotopes, such as, but not limited to, tritium ( 3 H), iodine-125( 125 I), or carbon-14 ( 14 C). All isotopic variations of the compounds of the present invention, whether radioactive or not, are intended to be encompassed within the scope of the present invention.

[0098] Stereoisomers (also known as optical isomers) of a compound include all chiral, diastereomeric and racemic forms of a structure unless a specific stereochemistry is explicitly indicated. Thus, the compounds used in the present technology include optical isomers enriched or resolved at any or all asymmetric atoms, as is clear from the depiction. Both racemic and diastereomeric mixtures, as well as individual optical isomers, can be isolated or synthesized to be substantially free of their enantiomeric or diastereomeric partners, and all of these stereoisomers are within the scope of the present technology.

[0099] The compounds of the present technology can exist as solvates, particularly hydrates. Hydrates can be formed during the preparation of the compounds or compositions containing the compounds, or hydrates can be formed over time due to the hygroscopic nature of the compounds. The compounds of the present technology can also exist as organic solvates, including DMF, ether, and alcohol solvates, among others. The identification and preparation of any particular solvate is within the skill of a person skilled in the art of synthetic organic or medicinal chemistry.

[0100] Unless otherwise indicated, the nomenclature of substituents not explicitly defined herein is obtained by naming the terminal end of the functional group followed by the adjacent functionality toward the point of attachment.

[0101] Stereoisomers (also known as optical isomers) of a compound include all chiral, diastereomeric and racemic forms of a structure unless a specific stereochemistry is explicitly indicated. Thus, the compounds used in the present technology include optical isomers enriched or resolved at any or all asymmetric atoms, as is clear from the depiction. Both racemic mixtures and d- or l-enriched stereomeric mixtures, as well as individual optical isomers, can be isolated or synthesized to be substantially free of their enantiomeric or diastereomeric partners, and all of these stereoisomers are within the scope of the present technology.

[0102] It is understood that in all of the above defined substituents, polymers obtained by defining a substituent that itself has an additional substituent (e.g., a substituted aryl having as a substituent a substituted aryl group that is itself substituted with a substituted aryl group) are not intended to be included herein. In such cases, the maximum number of such substituents is three. That is, each of the above definitions is constrained by the restriction that each functional group is substituted (in 1-3 positions), and any and all of those substituents may be substituted once more (in 1-3 positions).

[0103] It is understood that the above definitions are not intended to include impermissible substitution patterns (e.g., methyl substituted with five fluoro groups) that are well known to those of skill in the art.

[0104] Throughout this application, the subject matter refers to various embodiments of the compounds, compositions and methods. The various embodiments described are intended to provide various illustrative examples and should not be interpreted as descriptions of alternative species. Rather, it should be noted that the descriptions of the various embodiments provided herein may be of overlapping scope. The embodiments described herein are merely exemplary and are not intended to limit the scope of the technology.

[0105] compound The present disclosure provides compounds that exhibit both hydrophobicity and high affinity for mineralized forms of calcium and other metals, including biominerals. The compounds can be used in a variety of applications where both hydrophobicity and binding to metal-containing materials are desired.

[0106] More specifically, in a first aspect, the present disclosure provides a compound of formula IV [ka] or a salt, isomer or salt of an isomer thereof, wherein p is 10 to 30; q is 1 to 100; C is [ka] is selected from the group consisting of B is selected from the group consisting of a covalent bond and an ethyl group; A is selected from the group consisting of a covalent bond, acyl, acylamino, aminoacyl, acyloxy, thioacyl, aminocarbonyl, aminoacylcarbonyloxy, aminothiocarbonyl, aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy, aminosulfonyloxy, aminosulfonylamino, aminosulfonyl, amidino, and a carboxy ester; X is hydrogen, silyl, acyl, aminoacyl, thioacyl, aminocarbonyl, aminoacylcarbonyloxy, aminothiocarbonyl, aminosulfonyl, amidino, substituted sulfonyl, substituted sulfinyl, carboxy ester, phthalimide, OH, SO 3 H and PO 3 H.

[0107] In some embodiments, p is 12 to 28, 14 to 26, 14 to 24, 14 to 22, 14 to 20, 16 to 20, or 16 to 18. In some embodiments, p is 16. In some embodiments, q is 1 to 100, 5 to 90, 10 to 80, 15 to 70, 20 to 60, 25 to 50, 30 to 50, 40 to 50, or 40 to 45. In some embodiments, q is 43. In some embodiments, q is 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 49, or 50. In some embodiments, C is [ka] It is.

[0108] In some embodiments, the compound of formula IV is a compound of formula I [ka] or a salt, isomer or salt of an isomer thereof, wherein n is 10 to 30; m is 1 to 100.

[0109] In some embodiments, n is 20-25, 12-20, 14-18, or 14-16. In some embodiments, n is 14 or 16. In some embodiments, m is 1-90, 5-80, 10-70, 20-60, 30-50, or 38-50. In some embodiments, m is 43. In some embodiments, q is 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 49, or 50. In some embodiments, X is hydrogen, silyl, acyl, aminoacyl, thioacyl, aminocarbonyl, aminoacylcarbonyloxy, aminothiocarbonyl, aminosulfonyl, amidino, substituted sulfonyl, substituted sulfinyl, carboxy ester, phthalimide, OH, SO 3 H and PO 3 H.

[0110] In some embodiments, the compound of formula I is a compound of formula Ia [ka] or a salt, isomer or salt of an isomer thereof.

[0111] In some embodiments, the compound of formula I is represented by formula Ib [ka] It is a compound of the formula:

[0112] Pharmaceutical Compositions In a second aspect, the present disclosure provides a method for producing a method for treating a cancer cell comprising: Compound of Formula IV [ka] or a pharma- ceutically acceptable salt, isomer, or salt of an isomer thereof, p is 10 to 30; q is 1 to 100; C is [ka] is selected from the group consisting of B is selected from the group consisting of a covalent bond and an ethyl group; A is selected from the group consisting of a covalent bond, acyl, acylamino, aminoacyl, acyloxy, thioacyl, aminocarbonyl, aminoacylcarbonyloxy, aminothiocarbonyl, aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy, aminosulfonyloxy, aminosulfonylamino, aminosulfonyl, amidino, and a carboxy ester; X is hydrogen, silyl, acyl, aminoacyl, thioacyl, aminocarbonyl, aminoacylcarbonyloxy, aminothiocarbonyl, aminosulfonyl, amidino, substituted sulfonyl, substituted sulfinyl, carboxy ester, phthalimide, SO 3 H and PO 3 H, or a pharma- ceutically acceptable salt, isomer, or salt of an isomer thereof; Optionally, a pharma- ceutically acceptable excipient or diluent may be added. The present invention provides a pharmaceutical composition comprising:

[0113] In some embodiments, p is 12-28, 14-26, 14-24, 14-22, 14-20, 16-20, or 16-18. In some embodiments, p in the pharmaceutical composition is 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20. In some embodiments, the average value of p in the pharmaceutical composition is 12-28, 14-26, 14-24, 14-22, 14-20, 16-20, or 16-18. In some embodiments, the average value of p in the pharmaceutical composition is 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20.

[0114] In some embodiments, q is 1 to 100, 5 to 90, 10 to 80, 15 to 70, 20 to 60, 25 to 50, 30 to 50, 40 to 50, or 40 to 45. In some embodiments, q is 43. In some embodiments, q is 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 49, or 50. In some embodiments, the average value of q in the pharmaceutical composition is 1 to 100, 5 to 90, 10 to 80, 15 to 70, 20 to 60, 25 to 50, 30 to 50, 40 to 50, or 40 to 45. In some embodiments, the average value of q in the pharmaceutical composition is 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 49, or 50.

[0115] In some embodiments of the pharmaceutical composition, the molecular weight of the compound of formula IV is 1,500-5,000 daltons. In certain embodiments, the molecular weight of the compound of formula IV is 1,500-5,000 daltons. In certain embodiments, the molecular weight of the compound of formula IV is 2,000-4,500 daltons. In certain embodiments, the molecular weight of the compound of formula IV is 2,500-4,000 daltons. In certain embodiments, the molecular weight of the compound of formula IV is 3,000-3,500 daltons.

[0116] In some embodiments, C is [ka] It is.

[0117] In some embodiments of the pharmaceutical composition, the compound of formula IV is [ka] or a salt, isomer or salt of an isomer thereof, wherein n is 10 to 30; m is 1 to 100.

[0118] In some embodiments, n is 10 to 50, 20 to 25, 12 to 20, 14 to 18, or 14 to 16. In some embodiments, n is 14 or 16. In some embodiments, n is 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20. In some embodiments, the average value of n in the pharmaceutical composition is 10 to 50, 20 to 25, 12 to 20, 14 to 18, or 14 to 16. In some embodiments, the average value of n in the pharmaceutical composition is 14 or 16. In some embodiments, the average value of n in the pharmaceutical composition is 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20.

[0119] In some embodiments, m is 1 to 150, 1 to 140, 1 to 130, 1 to 120, 1 to 110, 1 to 100, 1 to 90, 5 to 80, 10 to 70, 20 to 60, 30 to 50, or 38 to 50. In some embodiments, m is 43. In some embodiments, m is 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 49, or 50. In some embodiments, the average value of m in the pharmaceutical composition is 1 to 150, 1 to 140, 1 to 130, 1 to 120, 1 to 110, 1 to 100, 1 to 90, 5 to 80, 10 to 70, 20 to 60, 30 to 50, or 38 to 50. In some embodiments, the average value of m in the pharmaceutical composition is 43. In some embodiments, the average value of m in the pharmaceutical composition is 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 49 or 50.

[0120] In some embodiments of the pharmaceutical composition, the molecular weight of the compound of formula I is 1,500-5,000 daltons. In certain embodiments, the molecular weight of the compound of formula I is 2,000-4,500 daltons. In certain embodiments, the molecular weight of the compound of formula I is 2,500-4,000 daltons. In certain embodiments, the molecular weight of the compound of formula I is 3,000-3,500 daltons.

[0121] In some embodiments, X is hydrogen, silyl, acyl, aminoacyl, thioacyl, aminocarbonyl, aminoacylcarbonyloxy, aminothiocarbonyl, aminosulfonyl, amidino, substituted sulfonyl, substituted sulfinyl, carboxy ester, phthalimide, OH, SO 3 H and PO 3 H.

[0122] In some embodiments, the compound of formula I is a compound of formula Ia [ka] or a salt, isomer or salt of an isomer thereof.

[0123] In some embodiments of the pharmaceutical composition, the average molecular weight of the compound of formula Ia is about 3500 daltons. In some embodiments, the average molecular weight of the compound of formula Ia is about 3200 daltons. In some embodiments, the average molecular weight of the compound of formula Ia is about 2500 daltons. In some embodiments, the average molecular weight of the compound of formula Ia is about 2000 daltons.

[0124] In some embodiments of the pharmaceutical composition, the compound of formula Ia is a compound of formula Ib [ka] It is a compound of the formula:

[0125] In some embodiments, the compound of formula I is represented by formula Ib [ka] It is a compound of the formula:

[0126] In some embodiments of the pharmaceutical composition, the average molecular weight of the compound of formula Ib is about 3500 daltons. In some embodiments, the average molecular weight of the compound of formula Ib is about 3200 daltons. In some embodiments, the average molecular weight of the compound of formula Ib is about 2500 daltons. In some embodiments, the average molecular weight of the compound of formula Ib is about 2000 daltons.

[0127] In some embodiments, the chain lengths of Formula Ib (16 and 43) are the average chain lengths of the compounds in the pharmaceutical composition.

[0128] In some embodiments of the pharmaceutical composition, the composition further comprises at least one additional phospholipid compound.

[0129] In some embodiments, the pharmaceutical composition further comprises: Compound of Formula II [ka] or a pharma- ceutically acceptable salt or isomer thereof.

[0130] In some embodiments, t is 10 to 30, 12 to 28, 14 to 25, 16 to 22, 16 to 20, or 18 to 20. In some embodiments, t is 14 or 16. In some embodiments, the average value of t in the pharmaceutical composition is 10 to 30, 12 to 28, 14 to 25, 16 to 22, 16 to 20, or 18 to 20. In some embodiments, the average value of t in the pharmaceutical composition is 14 or 16.

[0131] In some embodiments, y is 1 to 100, 5 to 90, 10 to 80, 20 to 70, 40 to 60, or 40 to 50. In some embodiments, y is 38 to 50. In some embodiments, the average value of y in the pharmaceutical composition is 1 to 100, 5 to 90, 10 to 80, 20 to 70, 40 to 60, or 40 to 50. In some embodiments, the average value of y in the pharmaceutical composition is 38 to 50.

[0132] In some embodiments of the pharmaceutical composition, the molecular weight of the compound of formula II is 1,500-5,000 daltons. In certain embodiments, the molecular weight of the compound of formula II is 2,000-4,500 daltons. In certain embodiments, the molecular weight of the compound of formula II is 2,500-4,000 daltons. In certain embodiments, the molecular weight of the compound of formula II is 3,000-3,500 daltons.

[0133] In some embodiments of the pharmaceutical composition, the compound of formula II is a compound of formula IIa [ka] or a pharma- ceutically acceptable salt or isomer thereof.

[0134] In some embodiments of the pharmaceutical composition, the average molecular weight of the compound of formula IIa is about 3000 daltons. In some embodiments, the average molecular weight of the compound of formula IIa is about 2800 daltons. In some embodiments, the average molecular weight of the compound of formula IIa is about 2600 daltons. In some embodiments, the average molecular weight of the compound of formula IIa is about 2400 daltons. In some embodiments, the average molecular weight of the compound of formula IIa is about 2200 daltons. In some embodiments, the average molecular weight of the compound of formula IIa is about 2000 daltons.

[0135] In some embodiments, the chain lengths of Formula IIa (16 and 43) are the average chain lengths of the compounds in the pharmaceutical composition.

[0136] In some embodiments of the pharmaceutical composition, the compound of formula II is represented by formula IIb [ka] It is a compound of the formula:

[0137] In some embodiments of the pharmaceutical composition, the average molecular weight of the compound of formula IIb is about 3000 daltons. In some embodiments, the average molecular weight of the compound of formula IIb is about 2800 daltons. In some embodiments, the average molecular weight of the compound of formula IIb is about 2600 daltons. In some embodiments, the average molecular weight of the compound of formula IIb is about 2400 daltons. In some embodiments, the average molecular weight of the compound of formula IIb is about 2200 daltons. In some embodiments, the average molecular weight of the compound of formula IIb is about 2000 daltons.

[0138] In some embodiments, the chain lengths of Formula IIb (16 and 43) are the average chain lengths of the compounds in the pharmaceutical composition.

[0139] In some embodiments, the pharmaceutical composition further comprises: Compound of Formula III [ka] or a pharma- ceutically acceptable salt or isomer thereof. In some embodiments, z is 10 to 30, 10 to 25, 12 to 20, 15 to 20, or 16 to 18. In some embodiments, z is 14 or 16. In some embodiments, the average value of z in the pharmaceutical composition is 10 to 30, 10 to 25, 12 to 20, 15 to 20, or 16 to 18. In some embodiments, the average value of z in the pharmaceutical composition is 14 or 16.

[0140] In some embodiments of the pharmaceutical composition, the molecular weight of the compound of formula III is 500-2,000 daltons. In certain embodiments, the molecular weight of the compound of formula III is 750-1,750 daltons. In certain embodiments, the molecular weight of the compound of formula III is 1,000-1,500 daltons. In certain embodiments, the molecular weight of the compound of formula III is 1,100-1,400 daltons. In certain embodiments, the molecular weight of the compound of formula III is 1,200-1,300 daltons.

[0141] In some embodiments of the pharmaceutical composition, the compound of formula III is of formula IIIa [ka] It is a compound of the formula:

[0142] In some embodiments of the pharmaceutical composition, the average molecular weight of the compound of formula IIIa is about 840 daltons. In some embodiments, the average molecular weight of the compound of formula IIIa is about 790 daltons. In some embodiments, the average molecular weight of the compound of formula IIIa is about 750 daltons. In some embodiments, the average molecular weight of the compound of formula IIIa is about 700 daltons. In some embodiments, the average molecular weight of the compound of formula IIIa is about 650 daltons.

[0143] In some embodiments, the chain length (16) of Formula IIIa is the average chain length of the compounds in the pharmaceutical composition.

[0144] In some embodiments, the pharmaceutical composition comprises 5 mol% or less of the compound of formula IV or a salt thereof. As used herein, mol% refers to the percentage of the number of molecules of a given lipid compound (e.g., a compound of formula IV, formula I, formula II, formula III or a salt, isomer or salt of an isomer) relative to the total number of molecules of all lipid compounds in the pharmaceutical composition. Similarly, in the context of a microsphere, mol% as used herein refers to the percentage of the number of molecules of a given lipid compound (e.g., a compound of formula IV, formula I, formula II, formula III or a salt, isomer or salt of an isomer thereof) relative to the total number of molecules of all lipid compounds in the microsphere. In certain embodiments, the pharmaceutical composition comprises 4 mol% or less of the compound of formula IV or a salt thereof. In certain embodiments, the pharmaceutical composition comprises 4 mol% or less of the compound of formula IV or a salt thereof. In certain embodiments, the pharmaceutical composition comprises 3 mol% or less of the compound of formula IV or a salt thereof. In certain embodiments, the pharmaceutical composition comprises 2 mol% or less of the compound of formula IV or a salt thereof. In certain embodiments, the pharmaceutical composition comprises 1 mol% or less of the compound of formula IV or a salt thereof.

[0145] In some embodiments, the pharmaceutical composition comprises 0.1-5 mol % of the compound of formula IV or a salt thereof. In some embodiments, the pharmaceutical composition comprises 0.1-10, 0.1-5, 0.5-5, 1-5, 1-4, 1-3, 2-3, 2-4, or 3-5 mol % of the compound of formula IV or a salt thereof.

[0146] In some embodiments, the composition comprises 0.01-5 mol % of a compound of formula I or a salt thereof. In some embodiments, the composition comprises 0.1-5 mol % of a compound of formula I or a salt thereof. In some embodiments, the pharmaceutical composition comprises 0.1-10, 0.1-5, 0.5-5, 1-5, 1-4, 1-3, 2-3, 2-4, or 3-5 mol % of a compound of formula I or a salt thereof.

[0147] In some embodiments, the pharmaceutical composition comprises 5 mol% or less of the compound of formula I or a salt thereof. In certain embodiments, the pharmaceutical composition comprises 4 mol% or less of the compound of formula I or a salt thereof. In certain embodiments, the pharmaceutical composition comprises 3 mol% or less of the compound of formula I or a salt thereof. In certain embodiments, the pharmaceutical composition comprises 2 mol% or less of the compound of formula I or a salt thereof. In certain embodiments, the pharmaceutical composition comprises 1 mol% or less of the compound of formula I or a salt thereof.

[0148] In some embodiments, the pharmaceutical composition comprises 0.01-5 mol% of a compound of formula Ia or Ib. In certain embodiments, the pharmaceutical composition comprises 0.1-5 mol% of a compound of formula Ia or Ib. In certain embodiments, the composition comprises 0.5-4.5 mol% of a compound of formula Ia or Ib. In certain embodiments, the composition comprises 1.0-4.0 mol% of a compound of formula Ia or Ib. In certain embodiments, the composition comprises 1.5-3.5 mol% of a compound of formula Ia or Ib. In certain embodiments, the composition comprises 2.0-3.0 mol% of a compound of formula Ia or Ib.

[0149] In some embodiments, the composition comprises 5 mol% or less of a compound of formula Ia or Ib. In some embodiments, the composition comprises 4.5 mol% or less of a compound of formula Ia or Ib. In some embodiments, the composition comprises 4.0 mol% or less of a compound of formula Ia or Ib. In some embodiments, the composition comprises 3.5 mol% or less of a compound of formula Ia or Ib. In some embodiments, the composition comprises 3.0 mol% or less of a compound of formula Ia or Ib. In some embodiments, the composition comprises 2.5 mol% or less of a compound of formula Ia or Ib. In some embodiments, the composition comprises 2.0 mol% or less of a compound of formula Ia or Ib. In some embodiments, the composition comprises 1.5 mol% or less of a compound of formula Ia or Ib. In some embodiments, the composition comprises 1.0 mol% or less of a compound of formula Ia or Ib. In some embodiments, the composition comprises 0.5 mol% or less of a compound of formula Ia or Ib. In some embodiments, the composition comprises 0.1 mol% or less of a compound of formula Ia or Ib. In some embodiments, the composition comprises no more than 0.05 mol % of a compound of formula Ia or Ib.

[0150] In some embodiments, the composition comprises 5-10 mol % of a compound of formula II or a salt thereof.

[0151] In some embodiments, the pharmaceutical composition comprises 10 mol% or less of a compound of formula II or a salt thereof. In certain embodiments, the pharmaceutical composition comprises 8 mol% or less of a compound of formula II or a salt thereof. In certain embodiments, the composition comprises 6 mol% or less of a compound of formula II or a salt thereof. In certain embodiments, the pharmaceutical composition comprises 4 mol% or less of a compound of formula II or a salt thereof. In certain embodiments, the pharmaceutical composition comprises 3 mol% or less of a compound of formula II or a salt thereof. In certain embodiments, the pharmaceutical composition comprises 2 mol% or less of a compound of formula II or a salt thereof. In certain embodiments, the pharmaceutical composition comprises 1 mol% or less of a compound of formula II or a salt thereof.

[0152] In some embodiments, the pharmaceutical composition comprises 5-10 mol % of the compound of formula II or a salt thereof. In some embodiments, the pharmaceutical composition comprises 5-20, 5-15, 5-10, 5-9.9, 5-9.6, 5-9, 5-9, 7-9, or 8-9 mol % of the compound of formula II or a salt thereof.

[0153] In some embodiments, the composition comprises 5.0-10.0 mol% of a compound of formula IIa or IIb. In certain embodiments, the composition comprises 5.5-9.5 mol% of a compound of formula IIa or IIb. In certain embodiments, the composition comprises 6.0-9.0 mol% of a compound of formula IIa or IIb. In certain embodiments, the composition comprises 6.5-8.5 mol% of a compound of formula IIa or IIb. In certain embodiments, the composition comprises 7.0-8.0 mol% of a compound of formula IIa or IIb.

[0154] In some embodiments, the composition comprises 10 mol% or less of a compound of formula IIa or IIb. In some embodiments, the composition comprises 9.5 mol% or less of a compound of formula IIa or IIb. In some embodiments, the composition comprises 9.0 mol% or less of a compound of formula IIa or IIb. In some embodiments, the composition comprises 8.5 mol% or less of a compound of formula IIa or IIb. In some embodiments, the composition comprises 8.0 mol% or less of a compound of formula IIa or IIb. In some embodiments, the composition comprises 7.5 mol% or less of a compound of formula IIa or IIb. In some embodiments, the composition comprises 7.0 mol% or less of a compound of formula IIa or IIb. In some embodiments, the composition comprises 6.5 mol% or less of a compound of formula IIa or IIb. In some embodiments, the composition comprises 6.0 mol% or less of a compound of formula IIa or IIb. In some embodiments, the composition comprises 5.5 mol% or less of a compound of formula IIa or IIb. In some embodiments, the composition comprises 5.0 mol% or less of a compound of formula IIa or IIb.

[0155] In some embodiments, the composition comprises 80-95 mol % of the compound of formula III or a salt thereof. In some embodiments, the pharmaceutical composition comprises 70-99, 75-98, 75-97, 80-95 mol % of the compound of formula III or a salt thereof.

[0156] In some embodiments, the pharmaceutical composition comprises 95 mol% or less of the compound of formula III or a salt thereof. In certain embodiments, the pharmaceutical composition comprises 85 mol% or less of the compound of formula III or a salt thereof. In certain embodiments, the pharmaceutical composition comprises 75 mol% or less of the compound of formula III or a salt thereof. In certain embodiments, the pharmaceutical composition comprises 65 mol% or less of the compound of formula III or a salt thereof. In certain embodiments, the pharmaceutical composition comprises 55 mol% or less of the compound of formula III or a salt thereof. In certain embodiments, the pharmaceutical composition comprises 45 mol% or less of the compound of formula III or a salt thereof. In certain embodiments, the pharmaceutical composition comprises 35 mol% or less of the compound of formula III or a salt thereof. In certain embodiments, the pharmaceutical composition comprises 25 mol% or less of the compound of formula III or a salt thereof. In certain embodiments, the pharmaceutical composition comprises 15 mol% or less of the compound of formula III or a salt thereof. In certain embodiments, the pharmaceutical composition comprises 5 mol% or less of the compound of formula III or a salt thereof.

[0157] In some embodiments, the composition comprises 80-95 mol% of the compound of formula IIIa. In certain embodiments, the composition comprises 82.5-92.5 mol% of the compound of formula IIIa. In certain embodiments, the composition comprises 85-90 mol% of the compound of formula IIIa. In certain embodiments, the composition comprises 87.5-92.5 mol% of the compound of formula IIIa.

[0158] In some embodiments of the pharmaceutical composition, the molar ratio of the compound of formula IV to the compound of formula II ranges from 1:1000 to 1:1. In certain embodiments of the pharmaceutical composition, the molar ratio of the compound of formula IV to the compound of formula II ranges from 1:500 to 1:1. In certain embodiments of the pharmaceutical composition, the molar ratio of the compound of formula IV to the compound of formula II ranges from 1:100 to 1:1. In certain embodiments, the molar ratio of the compound of formula IV to the compound of formula II ranges from 1:90 to 1:5. In certain embodiments, the molar ratio of the compound of formula IV to the compound of formula II ranges from 1:80 to 1:10. In certain embodiments, the molar ratio of the compound of formula IV to the compound of formula II ranges from 1:70 to 1:20. In certain embodiments, the molar ratio of the compound of formula IV to the compound of formula II ranges from 1:60 to 1:30. In certain embodiments, the molar ratio of the compound of formula IV to the compound of formula II ranges from 1:50 to 1:40.

[0159] In some embodiments of the pharmaceutical composition, the molar ratio of the compound of formula I to the compound of formula II ranges from 1:1000 to 1:1. In certain embodiments of the pharmaceutical composition, the molar ratio of the compound of formula I to the compound of formula II ranges from 1:500 to 1:1. In certain embodiments of the pharmaceutical composition, the molar ratio of the compound of formula I to the compound of formula II ranges from 1:100 to 1:1. In certain embodiments, the molar ratio of the compound of formula I to the compound of formula II ranges from 1:90 to 1:5. In certain embodiments, the molar ratio of the compound of formula I to the compound of formula II ranges from 1:80 to 1:10. In certain embodiments, the molar ratio of the compound of formula I to the compound of formula II ranges from 1:70 to 1:20. In certain embodiments, the molar ratio of the compound of formula I to the compound of formula II ranges from 1:60 to 1:30. In certain embodiments, the molar ratio of the compound of formula I to the compound of formula II ranges from 1:50 to 1:40.

[0160] In some embodiments of the pharmaceutical composition, the molar ratio of the compound of formula Ia to the compound of formula IIa ranges from 1:1000 to 1:1. In some embodiments of the pharmaceutical composition, the molar ratio of the compound of formula Ia to the compound of formula IIa ranges from 1:500 to 1:1. In some embodiments of the pharmaceutical composition, the molar ratio of the compound of formula Ia to the compound of formula IIa ranges from 1:100 to 1:1. In some embodiments, the molar ratio of the compound of formula Ia to the compound of formula IIa ranges from 1:90 to 1:5. In some embodiments, the molar ratio of the compound of formula Ia to the compound of formula IIa ranges from 1:80 to 1:10. In some embodiments, the molar ratio of the compound of formula Ia to the compound of formula IIa ranges from 1:70 to 1:20. In some embodiments, the molar ratio of the compound of formula Ia to the compound of formula IIa ranges from 1:60 to 1:30. In some embodiments, the molar ratio of the compound of formula Ia to the compound of formula IIa ranges from 1:50 to 1:40.

[0161] In some embodiments of the pharmaceutical composition, the molar ratio of the compound of formula Ib to the compound of formula IIb ranges from 1:1000 to 1:1. In some embodiments of the pharmaceutical composition, the molar ratio of the compound of formula Ib to the compound of formula IIb ranges from 1:500 to 1:1. In some embodiments of the pharmaceutical composition, the molar ratio of the compound of formula Ib to the compound of formula IIb ranges from 1:100 to 1:1. In some embodiments, the molar ratio of the compound of formula Ib to the compound of formula IIb ranges from 1:90 to 1:5. In some embodiments, the molar ratio of the compound of formula Ib to the compound of formula IIb ranges from 1:80 to 1:10. In some embodiments, the molar ratio of the compound of formula Ib to the compound of formula IIb ranges from 1:70 to 1:20. In some embodiments, the molar ratio of the compound of formula Ib to the compound of formula IIb ranges from 1:60 to 1:30. In some embodiments, the molar ratio of the compound of formula Ib to the compound of formula IIb ranges from 1:50 to 1:40.

[0162] In some embodiments of the pharmaceutical composition, the molar ratio of the compound of formula II to the compound of formula III ranges from 1:20 to 1:8. In certain embodiments, the molar ratio of the compound of formula II to the compound of formula III ranges from 1:18 to 1:10. In certain embodiments, the molar ratio of the compound of formula II to the compound of formula III ranges from 1:16 to 1:12. In certain embodiments, the molar ratio of the compound of formula II to the compound of formula III ranges from 1:15 to 1:13.

[0163] In some embodiments of the pharmaceutical composition, the molar ratio of the compound of formula IIa to the compound of formula IIIa ranges from 1:20 to 1:8. In some embodiments, the molar ratio of the compound of formula IIa to the compound of formula IIIa ranges from 1:18 to 1:10. In some embodiments, the molar ratio of the compound of formula IIa to the compound of formula IIIa ranges from 1:16 to 1:12. In some embodiments, the molar ratio of the compound of formula IIa to the compound of formula IIIa ranges from 1:15 to 1:13.

[0164] In some embodiments of the pharmaceutical composition, the molar ratio of the compound of formula IIb to the compound of formula IIIa ranges from 1:20 to 1:8. In some embodiments, the molar ratio of the compound of formula IIb to the compound of formula IIIa ranges from 1:18 to 1:10. In some embodiments, the molar ratio of the compound of formula IIb to the compound of formula IIIa ranges from 1:16 to 1:12. In some embodiments, the molar ratio of the compound of formula IIb to the compound of formula IIIa ranges from 1:15 to 1:13.

[0165] In some embodiments, the pharmaceutical composition comprises a compound of formula IV, optionally as formula I, or a pharma- ceutically acceptable salt, isomer, or salt of an isomer thereof; a compound of formula II, or a pharma- ceutically acceptable salt, isomer, or salt of an isomer thereof; and a compound of formula III, or a pharma- ceutically acceptable salt, isomer, or salt of an isomer thereof.

[0166] In some embodiments, the pharmaceutical composition comprises at least one ammonium salt of a compound of formula IV, formula I, formula II, and formula III.

[0167] In some embodiments, pharmaceutical compositions comprise a homogeneous population of compounds with the same carbon chain length.In some embodiments, pharmaceutical compositions comprise a heterogeneous population of lipid compounds with various lengths for each carbon chain.In such embodiments, the chain length expressed as a variable or specific number in formula IV, formula I, formula Ia, formula Ib, formula II, formula IIa, formula IIb, formula III, or formula IIIa refers to the average number of chain bonds of lipid compounds present in pharmaceutical compositions.

[0168] In some embodiments, the composition further comprises a fluid having a normal boiling point of less than 30°C.

[0169] In typical embodiments, the fluid is a gas at the temperatures and pressures present in the mammalian urinary tract. In preferred embodiments, the fluid is responsive to various forms of energy, such as electromagnetic, acoustic, microwave, photonic, or other. In certain embodiments, the fluid has low solubility in aqueous solutions and is suitable for use with air, nitrogen, argon, CO. 2 , sulfur hexafluoride, C fluoride 1~6 alkanes, or combinations thereof.

[0170] In some embodiments of the pharmaceutical composition, the fluid is a perfluorocarbon. In some embodiments, the fluid is selected from octafluoropropane, n-decafluorobutane, n-perfluoropropane, tetradecafluorohexane, and dodecafluoropentane. In certain embodiments, the fluid is n-decafluorobutane (also known as perfluorobutane).

[0171] In some embodiments of the pharmaceutical composition, the compound of formula IV (which in an exemplary embodiment is a compound of formula I); the compound of formula II; the compound of formula III; and the liquid having a normal boiling point of less than 30° C. can be assembled into a microsphere. Thus, in some embodiments, the pharmaceutical composition comprises a microsphere, the microsphere comprising a lipid shell surrounding a fluid having a normal boiling point of less than 30° C., the lipid shell comprising the compounds of formulas I, II and III.

[0172] The average diameter of the microspheres can be measured using any of the methods known in the art. In some embodiments, the average diameter is measured by electrozone sensing, for example using a Coulter counter. In some embodiments, the microspheres have an average diameter of about 0.1 microns to about 10 microns, or 0.1 microns to 10 microns, as measured by electrozone sensing. In certain embodiments, the microspheres have an average diameter of about 0.2 microns to about 9.5 microns. In certain embodiments, the microspheres have an average diameter of about 0.3 microns to about 9.0 microns. In certain embodiments, the microspheres have an average diameter of about 0.5 microns to about 8.5 microns. In certain embodiments, the microspheres have an average diameter of about 0.5 microns to about 8.0 microns. In certain embodiments, the microspheres have an average diameter of about 0.5 microns to about 7.5 microns. In certain embodiments, the microspheres have an average diameter of about 0.5 microns to about 7.0 microns. In certain embodiments, the microspheres have an average diameter of about 0.5 microns to about 6.5 microns. In certain embodiments, the microspheres have an average diameter of about 0.5 microns to about 6.0 microns. In certain embodiments, the microspheres have an average diameter of about 0.5 microns to about 5.5 microns. In certain embodiments, the microspheres have an average diameter of about 0.5 microns to about 5 microns. In certain embodiments, the microspheres have an average diameter of about 0.5 microns to about 4 microns. In certain embodiments, the microspheres have an average diameter of about 0.5 microns to about 3 microns. In certain embodiments, the microspheres have an average diameter of about 0.5 microns to about 2 microns. In certain embodiments, the microspheres have an average diameter of about 0.5 microns, 0.6 microns, 0.7 microns, 0.8 microns, 0.9 microns, 1 micron, or 5 microns.

[0173] In some embodiments, the pharmaceutical composition comprising the microspheres is a lyophilized powder or a dry concentrate.

[0174] In other embodiments, the pharmaceutical composition comprising the microspheres further comprises an aqueous medium, such as water, saline, or a buffered salt solution. In certain embodiments, the pharmaceutical composition comprises a phosphate buffer solution lacking calcium and magnesium ions. In certain embodiments, the composition further comprises a phosphate buffered saline solution.

[0175] In some embodiments, the pharmaceutical composition comprising the microspheres, whether in a lyophilized, dry concentrate or liquid formulation, comprises one or more of trehalose and PLASDONE K12 as excipients. PLASDONE K12 is a commercially available product.

[0176] Methods for Producing Bisphosphonate-PEG-Lipid Compounds In another aspect, the present disclosure provides a method of making a bisphosphonate-PEG-lipid compound.

[0177] An exemplary method for making bisphosphonate-PEG-lipid compounds is shown in Figure 2. The method includes the steps of (i) synthesizing the diacid form of a polyethylene glycol compound by oxoammonium catalyzed oxidation, (ii) synthesizing a PEG-lipid by NHS esterification and chromatography, and (iii) synthesizing a bisphosphonate-PEG-lipid by NHS esterification and chromatography.

[0178] In a first step, the synthesis method includes an oxidation reaction in which a polyethylene glycol compound is contacted with an oxidizing agent for a sufficient time to produce a dicarboxylic acid analog of said polyethylene glycol compound. In some embodiments, the oxidation reaction is an oxoammonium catalyzed oxidation reaction. In some embodiments, the oxidizing agent is NaClO 2 It is.

[0179] The synthesis method further includes a subsequent step of esterifying the resulting diacid form of PEG to a lipid, the esterification reaction being mediated by N-hydroxysuccinimide. In some embodiments, the resulting PEG-lipid is purified by chromatography.

[0180] The synthesis method further comprises the additional step of synthesizing the bisphosphonate-PEG-lipid by an esterification reaction. In some embodiments, the esterification reaction is mediated by N-hydroxysuccinimide. In some embodiments, the bisphosphonate-PEG-lipid is purified by chromatography.

[0181] In some embodiments, the bisphosphonate-PEG-lipid is a compound of formula IV. In some embodiments, the bisphosphonate-PEG-lipid is a compound of formula I. In some embodiments, the bisphosphonate-PEG-lipid is a compound of formula Ia. In some embodiments, the bisphosphonate-PEG-lipid is a compound of formula Ib.

[0182] How to prepare the PEG-lipid mixture In another aspect, the disclosure provides a method of making an assembleable phospholipid composition containing a fluid having a normal boiling point of less than 30° C. The method includes the steps of (a) blending PEG-lipids, including bisphosphonate-PEG-lipids, (b) homogenizing, and (c) filtering.

[0183] In an exemplary embodiment, step (a) comprises blending a bisphosphonate-PEG-lipid, a compound of formula II, and a compound of formula III.

[0184] In a typical embodiment, the bisphosphonate-PEG-lipid is a compound of formula IV. In a particular embodiment, the compound of formula IV is a compound of formula 1. In a particular embodiment, the compound of formula I is a compound of formula Ia. In a particular embodiment, the compound of formula I is a compound of formula Ib.

[0185] In some embodiments, the compound of formula II is a compound of formula IIa. In some embodiments, the compound of formula II is a compound of formula IIb. In some embodiments, the compound of formula III is a compound of formula IIIa.

[0186] In step (b), the PEG-lipid blended mixture is homogenized.

[0187] In step (c), the homogenized mixture is filtered.

[0188] Method for Producing Microspheres In a further aspect, the present disclosure provides a method for producing microspheres, the method comprising the steps of: (a) preparing a PEG-lipid mixture as described in the above section and combining with water, the mixture optionally further comprising at least one pharma- ceutically acceptable excipient; (b) combining the PEG-lipid mixture of step (a) with a fluid having a normal boiling point of less than 30° C. in a container; and (c) agitating or otherwise applying energy to the container containing the PEG-lipid mixture and the fluid from step (b) to obtain microspheres. In some embodiments, the microspheres obtained from step (c) are provided for therapeutic use. In this case, the microspheres may be in a liquid composition. The liquid composition may be in a container.

[0189] In some embodiments, the method further comprises step (d) of treating the composition containing the microspheres to extend its shelf life or expand the range of environmental conditions for storage. In one embodiment, step (d) comprises lyophilizing the composition containing the microspheres, although other methods known in the art can be used to extend the shelf life or expand the range of environmental conditions for storage of a microsphere solution.

[0190] In some embodiments, the method further comprises filling a container with the composition comprising the microspheres from step (c) or (d). In some embodiments, the method further comprises performing a particular processing step in the container. In some embodiments, the method further comprises stoppering the container comprising the microspheres from step (c) or (d).

[0191] In some embodiments, the method further comprises aseptic processing.

[0192] In some embodiments, the phospholipid composition of step (a) further comprises a compound of formula II, or a salt thereof. In some embodiments, the phospholipid composition of step (a) further comprises a compound of formula III, or a salt thereof. In some embodiments, the phospholipid composition of step (a) further comprises both a compound of formula II, or a salt thereof, and a compound of formula III, or a salt thereof.

[0193] In some embodiments, the compound of formula I or its salt used in the method is a compound of formula Ia or a compound of formula Ib. In some embodiments, the compound of formula II or its salt used in the method is a compound of formula IIa or a compound of formula IIb. In some embodiments, the compound of formula III or its salt used in the method is a compound of formula IIIa.

[0194] In some embodiments, the phospholipid composition of step (a) is filtered prior to step (b).

[0195] In some embodiments, the phospholipid composition is transferred to a container after step (a) and before step (b). In some embodiments, some or all of steps (a)-(d) are performed by a continuous process.

[0196] In some embodiments, the lyophilized microspheres are present as a lyophilized dry powder or water-free concentrate.

[0197] In some embodiments, the container may be stoppered under vacuum.

[0198] In some embodiments, lyophilized microspheres are more stable than microsphere solutions, hi some embodiments, lyophilized microspheres have a longer shelf life than microsphere solutions.

[0199] In some embodiments, the container is a unit dose container.

[0200] In some embodiments, the fluid is n-decafluorobutane.

[0201] In some embodiments, the covered container is filled with n-decafluorobutane.

[0202] In some embodiments, the phospholipid composition of step (a) comprises liposomes having an average diameter between 40 nanometers and 5000 nanometers. In some embodiments, the phospholipid composition of step (a) comprises liposomes having an average diameter between 100 nanometers and 1000 nanometers, between 200 nanometers and 900 nanometers, between 300 nanometers and 800 nanometers, between 400 nanometers and 700 nanometers, between 500 nanometers and 600 nanometers, between 100 nanometers and 200 nanometers, or between 10 nanometers and 100 nanometers. In some embodiments, the average diameter of the liposomes in the phospholipid composition of step (a) is about 50 nanometers.

[0203] In some embodiments, the method produces energy-responsive microspheres. For example, the microspheres produced by the method can collapse in response to the application of energy. In some embodiments, the energy is electromagnetic, acoustic, microwave, photonic, or other forms. The collapse of the microspheres can release energy, for example mechanical energy.

[0204] In some embodiments, the average diameter of the microspheres before lyophilization is about 0.1 microns to 1000 microns. In some embodiments, the average diameter of the microspheres before lyophilization is about 0.1 microns to 100 microns. In some embodiments, the average diameter of the microspheres before lyophilization is about 0.1 microns to 30 microns. In some embodiments, the average diameter of the microspheres before lyophilization is about 0.7 microns to 10 microns. In some embodiments, the average diameter of the microspheres before lyophilization is about 0.5 microns to 15.0 microns. In some embodiments, the average diameter of the microspheres before lyophilization is about 1.0 microns to 10.0 microns. In some embodiments, the average diameter of the microspheres before lyophilization is about 1.0 microns to 8.0 microns. In some embodiments, the average diameter of the microspheres before lyophilization is about 1.0 microns to 7.0 microns. In some embodiments, the average diameter of the microspheres before lyophilization is about 1.0 microns to 6.0 microns. In some embodiments, the average diameter of the microspheres before lyophilization is about 1.0 microns to 5.0 microns. In some embodiments, the average diameter of the microspheres before lyophilization is about 1.0 microns to 4.0 microns. In some embodiments, the average diameter of the microspheres before lyophilization is about 1.0 microns to 3.0 microns. In some embodiments, the average diameter of the microspheres before lyophilization is about 1.0 microns to 2.0 microns.

[0205] In some embodiments, the method comprises a step (d) comprising lyophilizing the composition comprising microspheres, wherein the loss of microspheres during lyophilization is 50% or less. In some embodiments, the loss of microspheres during lyophilization is 40% or less. In some embodiments, the loss of microspheres during lyophilization is 30% or less. In other embodiments, the loss of microspheres during lyophilization is 25% or less. In some embodiments, the loss of microspheres during lyophilization is 20% or less. In some embodiments, the loss of microspheres during lyophilization is 15% or less. In some embodiments, the loss of microspheres during lyophilization is 10% or less.

[0206] In some embodiments, the molecular weight of the compound of formula I is 1,500-5,000 daltons. In some embodiments, the molecular weight of the compound of formula I is 2,000-5,000 daltons. In some embodiments, the molecular weight of the compound of formula I is 2,000-4,500 daltons. In some embodiments, the molecular weight of the compound of formula I is 2,500-4,000 daltons. In some embodiments, the molecular weight of the compound of formula I is 3,000-3,500 daltons.

[0207] In some embodiments, the molecular weight of the compound of formula II is 1,500-5,000 daltons. In some embodiments, the molecular weight of the compound of formula II is 2,000-4,500 daltons. In some embodiments, the molecular weight of the compound of formula II is 2,500-4,000 daltons. In some embodiments, the molecular weight of the compound of formula II is 3,000-3,500 daltons.

[0208] In some embodiments, the molecular weight of the compound of formula III is between 500 and 2,000 daltons. In some embodiments, the molecular weight of the compound of formula III is between 750 and 1,750 daltons. In some embodiments, the molecular weight of the compound of formula III is between 1,000 and 1,500 daltons. In some embodiments, the molecular weight of the compound of formula III is between 1,100 and 1,400 daltons. In some embodiments, the molecular weight of the compound of formula III is between 1,200 and 1,300 daltons.

[0209] In some embodiments, the microspheres resulting from step (c) comprise 0.01-5 mol% of the compound of formula I. In some embodiments, the microspheres comprise 0.05-5 mol% of the compound of formula I. In some embodiments, the microspheres comprise 0.1-5 mol% of the compound of formula I. In some embodiments, the microspheres comprise 0.5-4.5 mol% of the compound of formula I. In some embodiments, the microspheres comprise 1.0-4.0 mol% of the compound of formula I. In some embodiments, the microspheres comprise 1.5-3.5 mol% of the compound of formula I. In some embodiments, the microspheres comprise 2.0-3.0 mol% of the compound of formula I.

[0210] In some embodiments, the microspheres resulting from step (c) comprise 5-9.9 mol% of the compound of formula II. In some embodiments, the microspheres comprise 5.5-9.5 mol% of the compound of formula II. In some embodiments, the microspheres comprise 6.0-9.0 mol% of the compound of formula II. In some embodiments, the microspheres comprise 6.5-8.5 mol% of the compound of formula II. In some embodiments, the microspheres comprise 7.0-8.0 mol% of the compound of formula II.

[0211] In some embodiments, the microspheres resulting from step (c) comprise 80-95 mol% of the compound of formula III. In some embodiments, the microspheres comprise 82.5-92.5 mol% of the compound of formula III. In some embodiments, the microspheres comprise 85-90 mol% of the compound of formula III. In some embodiments, the microspheres comprise 87.5-92.5 mol% of the compound of formula III.

[0212] In some embodiments, the microspheres resulting from step (c) contain 5 mol% or less of the compound of formula I. In some embodiments, the microspheres resulting from step (c) contain 4.5 mol% or less of the compound of formula I. In some embodiments, the microspheres contain 4.0 mol% or less of the compound of formula I. In some embodiments, the microspheres contain 3.5 mol% or less of the compound of formula I. In some embodiments, the microspheres contain 3.0 mol% or less of the compound of formula I. In some embodiments, the microspheres contain 2.5 mol% or less of the compound of formula I. In some embodiments, the microspheres contain 2.0 mol% or less of the compound of formula I. In some embodiments, the microspheres contain 1.5 mol% or less of the compound of formula I. In some embodiments, the microspheres contain 1.0 mol% or less of the compound of formula I. In some embodiments, the microspheres contain 0.5 mol% or less of the compound of formula I. In some embodiments, the microspheres contain 0.1 mol% or less of the compound of formula I. In some embodiments, the microspheres comprise 0.05 mol % or less of the compound of formula I.

[0213] In some embodiments, the microspheres resulting from step (c) contain 10 mol% or less of the compound of formula II. In some embodiments, the microspheres contain 9.5 mol% or less of the compound of formula II. In some embodiments, the microspheres contain 9.0 mol% or less of the compound of formula II. In some embodiments, the microspheres contain 8.5 mol% or less of the compound of formula II. In another embodiment, the microspheres contain 8.0 mol% or less of the compound of formula II. In another embodiment, the microspheres contain 7.5 mol% or less of the compound of formula II. In some embodiments, the microspheres contain 7.0 mol% or less of the compound of formula II. In some embodiments, the microspheres contain 6.5 mol% or less of the compound of formula II. In some embodiments, the microspheres contain 6.0 mol% or less of the compound of formula II. In some embodiments, the microspheres contain 5.5 mol% or less of the compound of formula II. In some embodiments, the microspheres contain 5.0 mol% or less of the compound of formula II.

[0214] In some embodiments, the microspheres resulting from step (c) contain 95 mol% or less of the compound of formula III. In some embodiments, the microspheres contain 92.5 mol% or less of the compound of formula III. In some embodiments, the microspheres contain 90 mol% or less of the compound of formula III. In some embodiments, the microspheres contain 87.5 mol% or less of the compound of formula III. In some embodiments, the microspheres contain 85.0 mol% or less of the compound of formula III. In some embodiments, the microspheres contain 82.5 mol% or less of the compound of formula III. In some embodiments, the microspheres contain 80.0 mol% or less of the compound of formula III.

[0215] In some embodiments, the average molecular weight of the compound of formula Ib in the microspheres of step (c) is about 3500 daltons. In some embodiments, the average molecular weight of the compound of formula Ib is about 3200 daltons. In some embodiments, the average molecular weight of the compound of formula Ib is about 2500 daltons. In some embodiments, the average molecular weight of the compound of formula Ib is about 2000 daltons.

[0216] In some embodiments, the average molecular weight of the compound of formula IIb in the microspheres of step (c) is about 3000 daltons. In some embodiments, the average molecular weight of the compound of formula IIb is about 2800 daltons. In some embodiments, the average molecular weight of the compound of formula IIb is about 2600 daltons. In some embodiments, the average molecular weight of the compound of formula IIb is about 2400 daltons. In some embodiments, the average molecular weight of the compound of formula IIb is about 2200 daltons. In some embodiments, the average molecular weight of the compound of formula IIb is about 2000 daltons.

[0217] In some embodiments, the average molecular weight of the compounds of formula IIIa in the microspheres of step (c) is about 840 daltons. In some embodiments, the average molecular weight of the compounds of formula IIIa is about 790 daltons. In some embodiments, the average molecular weight of the compounds of formula IIIa is about 750 daltons. In some embodiments, the average molecular weight of the compounds of formula IIIa is about 700 daltons. In some embodiments, the average molecular weight of the compounds of formula IIIa is about 650 daltons.

[0218] In some embodiments, the microspheres obtained from step (c) comprise 0.01-5 mol% of the compound of formula Ib. In some embodiments, the microspheres comprise 0.05-5 mol% of the compound of formula Ib. In some embodiments, the microspheres comprise 0.1-5 mol% of the compound of formula Ib. In some embodiments, the microspheres comprise 0.5-4.5 mol% of the compound of formula Ib. In some embodiments, the microspheres comprise 1.0-4.0 mol% of the compound of formula Ib. In some embodiments, the microspheres comprise 1.5-3.5 mol% of the compound of formula Ib. In some embodiments, the microspheres comprise 2.0-3.0 mol% of the compound of formula Ib.

[0219] In some embodiments, the microspheres resulting from step (c) comprise 5-9.9 mol% of the compound of formula IIb. In some embodiments, the microspheres comprise 6.0-9.0 mol% of the compound of formula IIb. In some embodiments, the microspheres comprise 6.5-8.5 mol% of the compound of formula IIb. In some embodiments, the microspheres comprise 7.0-8.0 mol% of the compound of formula IIb.

[0220] In some embodiments, the microspheres resulting from step (c) comprise 80-95 mol% of the compound of formula IIIa. In some embodiments, the microspheres comprise 82.5-92.5 mol% of the compound of formula IIIa. In some embodiments, the microspheres comprise 85-90 mol% of the compound of formula IIIa. In some embodiments, the microspheres comprise 87.5-92.5 mol% of the compound of formula IIIa.

[0221] In some embodiments, the microspheres resulting from step (c) contain 5 mol% or less of the compound of formula Ib. In some embodiments, the microspheres contain 4.5 mol% or less of the compound of formula Ib. In some embodiments, the microspheres contain 4.0 mol% or less of the compound of formula Ib. In some embodiments, the microspheres contain 3.5 mol% or less of the compound of formula Ib. In some embodiments, the microspheres contain 3.0 mol% or less of the compound of formula Ib. In some embodiments, the microspheres contain 2.5 mol% or less of the compound of formula Ib. In some embodiments, the microspheres contain 2.0 mol% or less of the compound of formula Ib. In some embodiments, the microspheres contain 1.5 mol% or less of the compound of formula Ib. In some embodiments, the microspheres contain 1.0 mol% or less of the compound of formula Ib. In some embodiments, the microspheres contain 0.5 mol% or less of the compound of formula Ib. In some embodiments, the microspheres contain 0.1 mol% or less of the compound of formula Ib. In some embodiments, the microspheres comprise no more than 0.05 mol % of a compound of formula Ib.

[0222] In some embodiments, the microspheres resulting from step (c) contain 10 mol% or less of the compound of formula IIb. In some embodiments, the microspheres contain 9.5 mol% or less of the compound of formula IIb. In some embodiments, the microspheres contain 9.0 mol% or less of the compound of formula IIb. In some embodiments, the microspheres contain 8.5 mol% or less of the compound of formula IIb. In some embodiments, the microspheres contain 8.0 mol% or less of the compound of formula IIb. In some embodiments, the microspheres contain 7.5 mol% or less of the compound of formula IIb. In some embodiments, the microspheres contain 7.0 mol% or less of the compound of formula IIb. In some embodiments, the microspheres contain 6.5 mol% or less of the compound of formula IIb. In some embodiments, the microspheres contain 6.0 mol% or less of the compound of formula IIb. In some embodiments, the microspheres contain 5.5 mol% or less of the compound of formula IIb. In some embodiments, the microspheres contain 5.0 mol% or less of the compound of formula IIb.

[0223] In some embodiments, the microspheres resulting from step (c) contain 95 mol% or less of the compound of formula IIIa. In some embodiments, the microspheres contain 92.5 mol% or less of the compound of formula IIIa. In some embodiments, the microspheres contain 90 mol% or less of the compound of formula IIIa. In some embodiments, the microspheres contain 87.5 mol% or less of the compound of formula IIIa. In some embodiments, the microspheres contain 85.0 mol% or less of the compound of formula IIIa. In some embodiments, the microspheres contain 82.5 mol% or less of the compound of formula IIIa. In some embodiments, the microspheres contain 80.0 mol% or less of the compound of formula IIIa.

[0224] In some embodiments, the molar ratio of the compound of formula Ia to the compound of formula IIa in the microspheres obtained from step (c) ranges from 1:1000 to 1:1. In some embodiments of the microspheres, the molar ratio of the compound of formula Ia to the compound of formula IIa ranges from 1:500 to 1:1. In some embodiments of the microspheres, the molar ratio of the compound of formula Ia to the compound of formula IIa ranges from 1:100 to 1:1. In some embodiments, the molar ratio of the compound of formula Ia to the compound of formula IIa ranges from 1:90 to 1:5. In some embodiments, the molar ratio of the compound of formula Ia to the compound of formula IIa ranges from 1:80 to 1:10. In some embodiments, the molar ratio of the compound of formula Ia to the compound of formula IIa ranges from 1:70 to 1:20. In some embodiments, the molar ratio of the compound of formula Ia to the compound of formula IIa ranges from 1:60 to 1:30. In some embodiments, the molar ratio of the compound of formula Ia to the compound of formula IIa ranges from 1:50 to 1:40.

[0225] In some embodiments of the pharmaceutical composition, the molar ratio of the compound of formula IIa to the compound of formula IIIa ranges from 1:20 to 1:8. In some embodiments, the molar ratio of the compound of formula IIa to the compound of formula IIIa ranges from 1:18 to 1:10. In some embodiments, the molar ratio of the compound of formula IIa to the compound of formula IIIa ranges from 1:16 to 1:12. In some embodiments, the molar ratio of the compound of formula IIa to the compound of formula IIIa ranges from 1:15 to 1:13.

[0226] In some embodiments of the microspheres, the molar ratio of the compound of formula Ib to the compound of formula IIb ranges from 1:1000 to 1:1. In some embodiments of the microspheres, the molar ratio of the compound of formula Ib to the compound of formula IIb ranges from 1:500 to 1:1. In some embodiments of the microspheres, the molar ratio of the compound of formula Ib to the compound of formula IIb ranges from 1:100 to 1:1. In some embodiments, the molar ratio of the compound of formula Ib to the compound of formula IIb ranges from 1:90 to 1:5. In some embodiments, the molar ratio of the compound of formula Ib to the compound of formula IIb ranges from 1:80 to 1:10. In some embodiments, the molar ratio of the compound of formula Ib to the compound of formula IIb ranges from 1:70 to 1:20. In some embodiments, the molar ratio of the compound of formula Ib to the compound of formula IIb ranges from 1:60 to 1:30. In some embodiments, the molar ratio of the compound of formula Ib to the compound of formula IIb ranges from 1:50 to 1:40.

[0227] Unit Dosage Form In a fourth aspect, the present disclosure provides a unit dosage container comprising a therapeutically effective amount of a pharmaceutical composition described herein.

[0228] In some embodiments, the unit dosage container comprises a phospholipid composition comprising a compound of Formula I, a compound of Formula II, and a compound of Formula III, and at least one pharma- ceutically acceptable excipient. In some embodiments, the unit dosage container further comprises a fluid having a normal boiling point of less than 30° C.

[0229] In some embodiments, the unit dose container comprises a microsphere, the microsphere comprising a compound of Formula I, a compound of Formula II, a compound of Formula III, a fluid having a normal boiling point of less than 30° C., and at least one pharma- ceutically acceptable excipient. The microspheres can be obtained by the methods described herein in connection with the methods of making the microspheres.

[0230] In some embodiments of the unit dosage form, the compound of formula I is a compound of formula Ia or Ib.

[0231] In some embodiments of the unit dosage form, the compound of formula II is a compound of formula IIa or IIb.

[0232] In some embodiments of the unit dosage form, the compound of formula III is a compound of formula IIIa.

[0233] In some embodiments, the fluid has a normal boiling point of less than 30° C. and is a gas at body temperature. In some embodiments, the fluid is air, CO 2 , sulfur hexafluoride, C fluoride 1~6 alkanes, or combinations thereof.

[0234] In some embodiments, the fluid is n-decafluorobutane.

[0235] In some embodiments, the unit dosage container composition further comprises trehalose and PLASDONE K12 as excipients. In some embodiments, the unit dosage container further comprises a phosphate buffer solution free of calcium and magnesium ions.

[0236] In some embodiments, the composition of the unit dosage container is capable of forming microspheres in the presence of water, hi some embodiments, the composition of the unit dosage container is a liquid composition comprising microspheres.

[0237] In some embodiments, the microspheres of the unit dosage container are present as a lyophilized dry powder or a water-free concentrate. In some embodiments, the lyophilized dry powder is a lyophalate that contains the microspheres. In some embodiments, the composition of the unit dosage container is a product obtained by reconstitution of a lyophilized formulation that contains the microspheres.

[0238] In some embodiments, the residual water content of the lyophilisate comprising microspheres is 10% by weight or less. In some embodiments, the residual water content of the lyophilisate comprising microspheres is 9.5% by weight or less. In some embodiments, the residual water content of the lyophilisate comprising microspheres is 9.0% by weight or less. In some embodiments, the residual water content of the lyophilisate comprising microspheres is 8.5% by weight or less. In some embodiments, the residual water content of the lyophilisate comprising microspheres is 8.0% by weight or less. In some embodiments, the residual water content of the lyophilisate comprising microspheres is 7.5% by weight or less. In some embodiments, the residual water content of the lyophilisate comprising microspheres is 7.0% by weight or less. In some embodiments, the residual water content of the lyophilisate comprising microspheres is 6.5% by weight or less. In some embodiments, the residual water content of the lyophilisate comprising microspheres is 6.0% by weight or less. In some embodiments, the residual water content of the lyophilisate comprising microspheres is 5.5% by weight or less. In some embodiments, the residual water content of the lyophilisate comprising microspheres is 5.0% by weight or less. In some embodiments, the residual water content of the lyophilisate comprising microspheres is 4.5% by weight or less. In some embodiments, the residual water content of the lyophilisate comprising microspheres is 4.0% by weight or less. In some embodiments, the residual water content of the lyophilisate comprising microspheres is 3.5% by weight or less. In some embodiments, the residual water content of the lyophilisate comprising microspheres is 3.0% by weight or less. In some embodiments, the residual water content of the lyophilisate comprising microspheres is 2.5% by weight or less. In some embodiments, the residual water content of the lyophilisate comprising microspheres is 2.0% by weight or less. In some embodiments, the residual water content of the lyophilisate comprising microspheres is 1.5% by weight or less. In some embodiments, the residual water content of the lyophilisate comprising microspheres is 1.0% by weight or less. In some embodiments, the residual water content of the lyophilisate comprising microspheres is 0.5% by weight or less.In some embodiments, the residual water content of the lyophilisate comprising microspheres is 0.4% by weight or less. In some embodiments, the residual water content of the lyophilisate comprising microspheres is 0.3% by weight or less. In some embodiments, the residual water content of the lyophilisate comprising microspheres is 0.2% by weight or less. In some embodiments, the residual water content of the lyophilisate comprising microspheres is 0.1% by weight or less. In some embodiments, the residual water content of the lyophilisate comprising microspheres is 0.01% by weight or less.

[0239] In some embodiments, the composition in the unit dosage container is prepared by any one of the methods described herein.

[0240] In some embodiments, the unit-dosage container is sealed by a crimped top cap fitted with a septum, hi some embodiments, the unit-dosage container is airtight.

[0241] kit In another aspect, the present disclosure provides a kit comprising at least one unit dosage container described herein and instructions for using said kit.

[0242] In some embodiments, the composition in each of the at least one unit-dose container is capable of forming microspheres in the presence of water.

[0243] In some embodiments of the kit, the unit dosage container further comprises trehalose and PLASDONE K12 as pharma- ceutically acceptable excipients.

[0244] In some embodiments, the kit further comprises a container containing an aqueous solution. In some embodiments, the aqueous solution is sterile water. In some embodiments, the aqueous solution is a saline solution ready for irrigation.

[0245] In some embodiments, the kit further comprises a syringe. In some embodiments, the kit further comprises a needle. In some embodiments, the kit further comprises a needleless syringe (e.g., a Mini-Spike®) that includes a sharp tip, where the needleless syringe is capable of penetrating the stopper.

[0246] In some embodiments, the kit further comprises a container of a fluid, the fluid being air, nitrogen, argon, CO 2 , sulfur hexafluoride, C fluoride 1~6 an alkane, an alkane, or a combination thereof. In some embodiments, the container is a syringe.

[0247] In some embodiments of the kit, C fluoride 1~6 The alkane is selected from octafluoropropane, n-decafluorobutane and dodecafluoropentane.

[0248] In some embodiments of the kit, the fluid is n-decafluorobutane.

[0249] In some embodiments, the kit further comprises a gel pad or ultrasound gel.

[0250] In some embodiments, the kit further comprises a device selected from a Mix2Vial® device and a vented vial adapter.

[0251] How to reconstruct In yet another aspect, the disclosure provides a method of reconstituting microspheres prepared according to any one of the methods described herein. In some embodiments, a lyophilisate containing microspheres is reconstituted. In some embodiments, the method of reconstitution comprises adding a sufficient amount of sterile water or saline solution to the microsphere solution described in the above section in a container. The method can further comprise adding a volume of gas to the container and shaking the container. Specifically, in some embodiments, the method of reconstituting microspheres comprises: (a) adding a sufficient amount of sterile water or saline solution to the microspheres in the container; (b) optionally adding a volume of gas to the vessel of step (a); (c) optionally shaking the container of step (b); Includes.

[0252] In some embodiments of the method of reconstitution, the amount of sterile water or saline solution is 1000 milliliters or less. In some embodiments of the method of reconstitution, the amount of sterile water or saline solution is 750 milliliters or less. In some embodiments of the method of reconstitution, the amount of sterile water or saline solution is 500 milliliters or less. In some embodiments of the method of reconstitution, the amount of sterile water or saline solution is 200 milliliters or less. In some embodiments of the method of reconstitution, the amount of sterile water or saline solution is 100 milliliters or less. In some embodiments, the amount of sterile water or saline solution is 90 milliliters or less. In some embodiments, the amount of sterile water or saline solution is 80 milliliters or less. In some embodiments, the amount of sterile water or saline solution is 70 milliliters or less. In some embodiments, the amount of sterile water or saline solution is 60 milliliters or less. In some embodiments, the amount of sterile water or saline solution is 50 milliliters or less. In some embodiments, the amount of sterile water or saline solution is 40 milliliters or less. In some embodiments, the amount of sterile water or saline solution is 30 milliliters or less. In some embodiments, the amount of sterile water or saline solution is 20 milliliters or less. In some embodiments, the amount of sterile water or saline solution is 10 milliliters or less. In some embodiments, the amount of sterile water or saline solution is 5 milliliters or less. In some embodiments, the amount of sterile water or saline solution is 1 milliliter or less. In some embodiments, the amount of sterile water or saline solution is 0.5 milliliters or less. In some embodiments, the amount of sterile water or saline solution is 0.3 milliliters or less.

[0253] In some embodiments, the amount of sterile water or saline solution added is sufficient to produce a homogenous mixture containing the reconstituted microspheres.

[0254] In some embodiments of the method of reconstitution, the shaking of the container lasts for 180 seconds or less. In some embodiments, the shaking of the container lasts for 160 seconds or less. In some embodiments, the shaking of the container lasts for 140 seconds or less. In some embodiments, the shaking of the container lasts for 120 seconds or less. In some embodiments, the shaking of the container lasts for 100 seconds or less. In some embodiments, the shaking of the container lasts for 80 seconds or less. In some embodiments, the shaking of the container lasts for 60 seconds or less. In some embodiments, the shaking of the container lasts for 40 seconds or less. In some embodiments, the shaking of the container lasts for 20 seconds or less. In some embodiments, the shaking of the container lasts for 10 seconds or less. In some embodiments, the shaking of the container lasts for 5 seconds or less.

[0255] In some embodiments of the method of reconstitution, the shaking of the container lasts for 160 seconds or less. In some embodiments, the shaking of the container lasts for at least 140 seconds. In some embodiments, the shaking of the container lasts for at least 120 seconds. In some embodiments, the shaking of the container lasts for at least 100 seconds. In some embodiments, the shaking of the container lasts for at least 80 seconds. In some embodiments, the shaking of the container lasts for at least 60 seconds. In some embodiments, the shaking of the container lasts for at least 40 seconds. In some embodiments, the shaking of the container lasts for at least 20 seconds. In some embodiments, the shaking of the container lasts for at least 10 seconds. In some embodiments, the shaking of the container lasts for at least 5 seconds.

[0256] Treatment In a final aspect, the present disclosure provides a method of treating a medical condition involving an abnormal or obstructive mass. In some embodiments, the medical condition includes kidney stones, urinary stones, bile duct stones, blood clots, fibroids, cancerous tumors, and atheromatous plaques. In some embodiments, the subject has urolithiasis.

[0257] In some embodiments, the methods include administering to a subject having a medical condition an effective amount of a reconstituted microsphere solution described herein so as to contact the microspheres with an abnormal or obstructive mass (e.g., urinary stones, kidney stones, bile duct stones, blood clots, fibroids, cancerous tumors, and atheromatous plaques) and directionally applying energy to the abnormal or obstructive mass in the subject at a frequency that excites the fluid within the microspheres.

[0258] In some embodiments, the reconstituted microsphere solution is administered to the subject's ureter through a urinary catheter.

[0259] In some embodiments, the applied energy is electromagnetic, acoustic, microwave, photonic, laser, or other form.

[0260] In some embodiments, the applied energy is ultrasound, hi some embodiments, the applied energy is acoustic energy.

[0261] In some embodiments, the acoustic energy is ultrasonic energy in the frequency range of 100 kilohertz (kHz) to 2 megahertz (MHz). In some embodiments, the acoustic energy is ultrasonic energy in the frequency range of 200 kilohertz (kHz) to 1.5 megahertz (MHz). In some embodiments, the acoustic energy is ultrasonic energy in the frequency range of 300 kilohertz (kHz) to 1.2 megahertz (MHz). In some embodiments, the acoustic energy is ultrasonic energy in the frequency range of 500 kilohertz (kHz) to 1 megahertz (MHz).

[0262] In some embodiments, the applied ultrasonic energy is associated with a peak pressure in the range of 0.1 MPa to 10 MPa. In some embodiments, the applied ultrasonic energy is associated with a peak pressure in the range of 1 MPa to 10 MPa. In some embodiments, the applied ultrasonic energy is associated with a peak pressure in the range of 2 MPa to 9 MPa. In some embodiments, the applied ultrasonic energy is associated with a peak pressure in the range of 4 MPa to 8 MPa. In some embodiments, the applied ultrasonic energy is associated with a peak pressure in the range of 5 MPa to 7 MPa.

[0263] In some embodiments, the applied energy is generated intraluminal energy from a pulsed solid-state laser.

[0264] In some embodiments, the wavelength of the laser energy ranges from 1000 nm to 2500 nm. In some embodiments, the wavelength of the laser energy ranges from 2050 nm to 2150 nm. In some embodiments, the vaporization of the liquid phase by the laser energy is associated with a moving phase boundary that creates a pressure effect on the liquid phase.

[0265] In some embodiments, the laser energy has a frequency in the range of 1 kHz to 1 MHz, hi some embodiments, the laser energy has a frequency in the range of 1 kHz to 1 MHz, 10 kHz to 500 kHz, 50 kHz to 100 kHz, or 10 kHz to 50 kHz.

[0266] In some embodiments, the energy is applied for an amount of time sufficient to fragment the urinary stone.

[0267] In some embodiments, the amount of time for which the energy is applied is 100 minutes or less. In some embodiments, the amount of time for which the energy is applied is 90 minutes or less. In some embodiments, the amount of time for which the energy is applied is 80 minutes or less. In some embodiments, the amount of time for which the energy is applied is 70 minutes or less. In some embodiments, the amount of time for which the energy is applied is 60 minutes or less. In some embodiments, the amount of time for which the energy is applied is 50 minutes or less. In some embodiments, the amount of time for which the energy is applied is 40 minutes or less. In some embodiments, the amount of time for which the energy is applied is 30 minutes or less. In some embodiments, the amount of time for which the energy is applied is 25 minutes or less. In some embodiments, the amount of time for which the energy is applied is 20 minutes or less. In some embodiments, the amount of time for which the energy is applied is 15 minutes or less. In some embodiments, the amount of time for which the energy is applied is 10 minutes or less.

[0268] In some embodiments, the applied photonic energy causes a change in volume or other cavitation effect in the microspheres.

[0269] In some embodiments, cavitation of the microspheres induces pressure gradient changes and mechanical effects on the urinary stones around the reconstituted microspheres.

[0270] In some embodiments, pressure gradient changes and other mechanical actions can fragment urinary stones.

[0271] In some embodiments, the subject is a human. In some embodiments, the subject is an animal. EXAMPLES

[0272] The following synthetic and biological examples are offered to illustrate the present technology and are not to be construed in any way as limiting the scope of the technology.

[0273] All temperatures are in degrees Celsius unless otherwise stated.

[0274] Efforts have been made to ensure accuracy with respect to numbers used (eg, amounts, temperature, etc.), but some experimental error and deviation should be allowed for.

[0275] Any method that is functionally equivalent is within the scope of the technology. Various modifications of the technology in addition to those described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims.

[0276] In the examples below, the following abbreviations have the following meanings: If an abbreviation is not defined, it has its generally accepted meaning. aq. = aqueous LC-MS = Liquid Chromatography-Mass Spectrometry MS=mass spectrometry THF = tetrahydrofuran NaHCO 3 = Sodium bicarbonate DIEA = diisopropylethylamine MS=mass spectrometry NaH = sodium hydride o / n=overnight HATU = 1-[bis(dimethylamino)methylene]-1H-1,2,3-trizolo[4,5-b]pyridinium 3-oxide hexafluorophosphate rt=room temperature LAH=Lithium Aluminum Hydride DCM = dichloromethane DMF = Dimethylformamide DMSO = dimethyl sulfoxide equiv.=equivalent EtOAc = ethyl acetate EtOH = ethanol g = grams h)=time HCl = Hydrochloric Acid HPLC = High Performance Liquid Chromatography HOAc = acetic acid M = molar concentration MeOH = methanol mg = milligrams mL = milliliters mmol = millimolar mp = melting point m / z=mass-to-charge ratio NaCl = Sodium chloride Na 2 CO 3 = Sodium carbonate NMR=nuclear magnetic resonance NaOH = Sodium hydroxide Na 2 SO 4 = Sodium sulfate NHS = n-hydroxysuccinimide ppm=parts per million TLC = Thin Layer Chromatography UV = ultraviolet wt% = weight percent μM = micromolar

[0277] General experiment details: The final compound and phospholipid composition were confirmed by NMR. 1 H-NMR, 31 P-NMR, 13 C-NMR spectra were obtained using CDCl 3 (Residual internal standard CHCl 3 = δ 7.26), DMSO-d 6 (Residual internal standard CD 3 SOCD 2 H=δ2.50), methanol-d 4 (Residual internal standard CD 2 HOD=δ3.20), or acetone-d 6 (Residual internal standard CD 3 COCD 2 H=δ2.05), or CDCl 3 and methanol-d 4The spectra were recorded in a mixture with . Reported chemical shifts (δ) are given in parts per million (ppm) and coupling constants (J) are given in Hertz (Hz). Spin multiplicities are reported as s = singlet, bs = broad singlet, bm = broad multiplet, d = doublet, t = triplet, q = quartet, p = pentuplet, dd = doublet of doublet, ddd = doublet of doublet of doublet, dt = doublet of triplet, td = triplet of doublet, tt = triplet of triplet, and m = multiplet.

[0278] Example 1: Synthesis of compounds of formula Ib Step 1 - Synthesis of PEG2DA PEG2000 is dissolved in acetonitrile and warmed to 40°C. Once dissolved, an aqueous potassium phosphate buffer solution adjusted to approximately pH 7.5 with phosphoric acid is charged, followed by the addition of TEMPO. Aqueous solutions of sodium chlorite and sodium hypochlorite are then charged simultaneously to the reaction mixture over 30 minutes to 1 hour. Once charging is complete, the reaction is stirred at 40°C for a minimum of 24-48 hours. After the minimum stirring time, the reaction is assayed for completion by TLC analysis. Once deemed complete, the mixture is cooled to 0°C and quenched with aqueous sodium thiosulfate. The quenched solution is then acidified to pH<3 with aqueous hydrochloric acid, and the organic material is extracted with a chloroform / methanol / water partition. The solvent is then removed from the organic phase by rotary evaporation, and the material is dried in a toluene cycle. The crude material is then purified by precipitation from toluene with diethyl ether. Figure 8 shows the solubility of purified PEG2DA. 1 The H-NMR spectrum is shown.

[0279] Step 2 - Synthesis of DSPE-PEG 2-COOH PEG2DA was dissolved in toluene and warmed to 90°C. CDI was added in small portions to control carbon dioxide evolution. Once all solids had dissolved and all effervescence had ceased, solid DSPE was added to the reaction mixture, followed by triethylamine. The mixture was stirred at 90°C for 12-24 hours, at which point completion of the reaction was confirmed by TLC. Once complete, the reaction mixture was quenched with 5-10 mL of methanol and cooled to ambient temperature. Once cooled, the solution was diluted with chloroform and partitioned against 1M aqueous hydrochloric acid to remove the imidazole, followed by a brine wash. The mixture was neutralized with ammonium hydroxide, after which the bulk solvent was removed by rotary evaporation. The crude mixture was then sequentially chromatographed first on normal phase media (chloroform / methanol / ammonium hydroxide gradient) and then on reverse phase media (methanol / water gradient) with a column wash with sodium chloride to yield the sodium salt of DSPE-PEG2-COOH. Figures 9 and 10 show the elution and elution of DSPE-PEG2-COOH, respectively. 1 H-NMR and 31 The P-NMR spectrum is shown.

[0280] Step 3 - Synthesis of Compounds of Formula Ib Prior to reaction, alendronate was dissolved in tetrabutylammonium hydroxide (40 wt% solution in water) and water was azeotropically removed using toluene, followed by drying under vacuum. After preparation of alendronate-TBA, DSPE-PEG2-COOH was dissolved in a mixture of 85:15 anhydrous chloroform / anhydrous dimethylformamide and warmed to 40°C. N-hydroxysuccinimide (NHS) was added to the solution, followed by 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDAC), and the mixture was stirred at 40°C for 4-6 hours. After the allotted time, 1 DSPE-PEG 2-COO-NHS ester formation was assayed using H NMR spectroscopy ( 1Typical reaction completion by H-NMR analysis was >75%. Once DSPE PEG2 COO-NHS ester formation was confirmed, the previously prepared alendronate-TBA salt was dissolved in anhydrous chloroform and added directly to the reaction vessel, followed by triethylamine. The reaction temperature was then raised to 50°C and stirred at that temperature for 18-24 hours, at which point the reaction was assayed for completion by TLC. Upon completion, the reaction mixture was partitioned three times against 1M aqueous hydrochloric acid to remove excess alendronate, followed by two brine washes to remove excess acid. The mixture was neutralized with ammonium hydroxide, after which the bulk solvent was removed by rotary evaporation. The material was then treated with Dowex® 50WX8 hydrogen form ion exchange resin to remove the bulk tetrabutylammonium counterion. The resin was filtered, the bulk solvent removed from the filtrate, and the material was then chromatographed on a reversed phase medium (methanol / water gradient) with a column wash with ammonium chloride to provide compound of formula Ib. 11 and 12 respectively show the compounds of formula Ib having the structure 1 H-NMR spectrum and 31 The P-NMR spectrum is shown: [ka] The methods for synthesizing compounds of formula Ib described herein are summarized below: [ka]

[0281] Example 2: Synthesis of Microspheres The compound of formula Ib, prepared as described in Example 1, was used in combination with other lipid compositions - DSPE-PEG2K (Compound of Formula IIb) [ka] and DSPC (Compound of Formula IIIa) [ka] As well as mixed with water.

[0282] Mixture (Figure 14) 31 The P-NMR spectrum shows three peaks, each corresponding to each lipid composition, the compound of formula Ib, DSPC or DSPE-PEG2K. The signal of each peak indicates the relative amount of the compound of formula Ib (28.37 for "DSPE PEG alendronate"), DSPC (1363.68 for "DSPC"), and DSPE-PEG2K (107.55 for "DSPE PEG") in the mixture.

[0283] The liquid phase of the mixture containing the compound of formula Ib, DSPC and DSPE-PEG2K was processed with a homogenizer in multiple passes until the desired diameter and PDI was achieved. Samples from each pass were analyzed for size distribution using dynamic light scattering (DLS), the results of which are shown in Figure 4. The formulation was diluted with phosphate buffered saline and analyzed with a Mobius (Wyatt).

[0284] n-Decafluorobutane (C 4 F 10 ) was added to the lipid mixture and the mixture was stirred for 1-2 min. Images of the lipid mixture before (left) and after (right) the addition of n-decafluorobutane and stirring step are provided and compared in Figure 5. The images show the qualitative differences in the formulations.

[0285] Microspheres were characterized for particle number density and particle diameter by electrozone sensing using a Beckman Coulter Multisizer 4e with a 30 µm aperture. Sample volumes ranged from 1 to 10 µL in 100 mL of Isoton II diluent. Exemplary results are shown in Figure 7. The results show that microspheres were produced with average sizes ranging from 0.7 to 2 µm.

[0286] Example 3: Accumulation assay The microspheres produced as described in Examples 1 and 2 were characterized using a Beckman Coulter Multisizer 4e in a time course study while being incubated with hydroxyapatite beads. The microspheres were analyzed by the Multisizer for particle density at various time points. The change in concentration of microspheres was used to calculate the number of microspheres that accumulated on the surface of the hydroxyapatite beads. A control microsphere sample that does not contain the compound of formula Ib was also analyzed.

[0287] As summarized in Figure 6, the experiments demonstrated significant accumulation of microspheres bearing the compound of formula Ib on the hydroxyapatite beads over the time course study, suggesting that the microspheres containing the compound of formula Ib have a high affinity for the hydroxyapatite beads.

[0288] Example 4: Headspace Analysis A headspace sample was drawn directly from the container containing the pharmaceutical composition of the compound of formula Ib and n-decafluorobutane using a manual gas chromatography syringe. The headspace sample was immediately injected into the GC. The GC signal from the experiment is shown in Figure 13, which shows a peak indicative of n-decafluorobutane.

[0289] Example 5: Use of Microspheres with an External Acoustic Energy Source for the Treatment of Urolithiasis Microspheres produced as described in Examples 1 and 2 were administered to patients diagnosed with urinary stones via a cystoscope-placed 5Fr catheter. The patient presented with acute renal colic and had a diagnosis of stone disease confirmed by CT scan. A catheter was placed in the diseased side of the patient's upper urinary tract and a syringe containing the microsphere solution was placed connected to the distal end of the catheter, after which the cystoscope was removed. A 0.5-1.0 mL volume of the microsphere solution was injected at multiple intervals over the course of the procedure, which spanned a period of 20-90 minutes. Acoustic energy was applied at multiple intervals over the course of the procedure. The acoustic energy source used, a SmartSphere console with a treatment head designed to be applied to the skin of the patient's lower back or groin, was created to interact with microspheres at or near the surface of the stone, causing erosion, pitting and fragmentation of the stone, and was shown to be safe in extensive studies in porcine models. Many patients with urinary stones have been successfully treated using this method.

[0290] While the present invention has been particularly shown and described with reference to preferred and various alternative embodiments, it will be understood by those skilled in the art that various changes in form and detail can be made therein without departing from the spirit and scope of the invention.

[0291] All references, issued patents, and patent applications cited within the body of this specification are hereby incorporated by reference in their entirety for all purposes. The present invention provides, for example, the following items. (Item 1) Compound of Formula IV [ka] Formula IV 1 or a salt, isomer or salt of an isomer thereof, wherein p is 10 to 30; q is 1 to 100; C is

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

Claims

1. Compound of Formula Ia [C101] or a salt thereof.

2. Compounds of Formula I [C102] or a salt thereof, wherein n is 10 to 30; m is 1 to 100; X is hydrogen, silyl, acyl, aminoacyl, thioacyl, aminocarbonyl, aminoacyl, carbonyloxy, aminothiocarbonyl, aminosulfonyl, amidino, substituted sulfonyl, substituted sulfinyl, carboxy ester, phthalimide, OH, SO 3 H or PO 3 H, or a salt thereof; Compound of Formula II [chemical 103] or a salt thereof, and Compound of Formula III [chemical 104] or a salt thereof, wherein t is 10 to 30; y is 1 to 100; z is 10 to 30; Compound or salt thereof A pharmaceutical composition comprising: Optionally, a pharmaceutical composition comprising at least one excipient or diluent.

3. The compound of formula I is a compound of formula Ia [C105] or a salt thereof.

4. The compound of formula II is a compound of formula IIa [C106] or a salt thereof.

5. The compound of formula III is a compound of formula IIIa [C107] or a salt thereof.

6. The composition, 0.01 to 5 mol % of said compound of formula I, 5 to 9.9 mol % of the compound of formula II, and 80 to 95 mol % of said compound of formula III The pharmaceutical composition of claim 2 , comprising:

7. The composition may further comprise air, nitrogen, argon, carbon dioxide (CO 2 ), sulfur hexafluoride and C fluoride 1~6 3. The pharmaceutical composition of claim 2, comprising a fluid having a normal boiling point below 30° C. selected from the group consisting of alkanes.

8. The fluoride C 1~6 8. The pharmaceutical composition of claim 7, wherein the alkane is selected from the group consisting of octafluoropropane, n-decafluorobutane and dodecafluoropentane.

9. 8. The pharmaceutical composition of claim 7, wherein the composition comprises microspheres, the microspheres comprising a lipid shell surrounding the fluid having a normal boiling point of less than 30°C, the lipid shell comprising the compounds of Formulas I, II and III.

10. 10. The pharmaceutical composition of claim 9, wherein the microspheres have an average diameter of about 0.1 microns to 10 microns.

11. 10. The pharmaceutical composition of claim 9, wherein the composition is a lyophilized dry powder or a water-free concentrate.

12. 10. The pharmaceutical composition of claim 9, wherein the composition further comprises water, a saline solution, or a buffered salt solution.

13. 10. The pharmaceutical composition of claim 9, wherein the composition further comprises trehalose.

14. 10. A pharmaceutical composition according to claim 9 for use in a method for treating urolithiasis, the method comprising: administering the pharmaceutical composition to a subject with urolithiasis by a route of administration effective to contact the microspheres with urinary stones; and applying energy to the microspheres; thereby creating a cavitation effect within or around said urinary stone.

15. The compound of formula I is a compound of formula Ia [C108] or a salt thereof.

16. The compound of formula I may be a compound of formula Ib: [C109] The pharmaceutical composition of claim 14,

17. The compound of formula I may be a compound of formula Ib: [C110] and The compound of formula II is a compound of formula IIb [C111] and The compound of formula III is a compound of formula IIIa [C112] The pharmaceutical composition according to claim 2 ,

18. The composition, 0.01-5 mol % of said compound of formula Ib, 5-9.9 mol % of said compound of formula IIb, and 80-95 mol % of said compound of formula IIIa 20. The pharmaceutical composition of claim 17, comprising:

19. 19. The pharmaceutical composition of claim 18, wherein the composition further comprises n-decafluorobutane.

20. 20. The pharmaceutical composition of claim 19, wherein the composition comprises microspheres, the microspheres comprising a lipid shell encapsulating a fluid having a normal boiling point of less than 30° C., the lipid shell comprising the compound of formula Ib, IIb and IIIa.

21. Compound of formula Ia: [C113] Or its salt.

22. Compound of formula Ib: [C114] .

23. 1. A method for producing microspheres, the method comprising: (a) Below: Compounds of Formula I [C56] or a salt thereof; Compound of Formula II [C57] or a salt thereof; Compound of Formula III [C58] or a salt thereof, Optionally, at least one pharma- ceutically acceptable excipient, and water preparing a formulation for making microspheres comprising: During the ceremony, n is 10 to 30; m is 1 to 100; t is 10 to 30; y is 1 to 100; z is 10 to 30; X is hydrogen, silyl, acyl, aminoacyl, thioacyl, aminocarbonyl, aminoacylcarbonyloxy, aminothiocarbonyl, aminosulfonyl, amidino, substituted sulfonyl, substituted sulfinyl, carboxy ester, phthalimide, OH, SO 3 H and PO 3 H.

24. moreover, (b) combining the formulation of step (a) with a fluid having a normal boiling point of less than 30° C. in a container; (c) agitating the vessel containing the formulation and fluid from step (b), thereby obtaining microspheres.

24. The method of claim 23, comprising:

25. moreover, (d) treating the microsphere solution from step (c) to extend its shelf life or to expand the range of environmental conditions for storage.

25. The method of claim 24, comprising:

26. moreover, (e) stoppering, optionally under vacuum, the container containing the microspheres from step (c) or (d).

26. The method of claim 24 or 25, comprising:

27. 26. The method of any one of claims 23 to 25, wherein the formulation of step (a) is filtered prior to step (b).

28. 28. The method of claim 27, wherein said processing step (d) is lyophilizing said microsphere solution.

29. 26. The method of any one of claims 24 to 25, wherein the microspheres from step (c) have an average diameter of about 0.1 to 100 μm.

30. 26. The method of any one of claims 23 to 25, wherein the molar ratio of said compound of formula I to said compound of formula II in said formulation ranges from 1:100 to 1:

1.

31. 26. The method of any one of claims 23 to 25, wherein the molar ratio of said compound of formula II to said compound of formula III in said formulation ranges from 1:20 to 1:

8.

32. The method of claim 30, wherein the compound of formula I is a compound of formula Ib and the compound of formula II is a compound of formula IIb, and the molar ratio of the compound of formula Ib to the compound of formula IIb in the microspheres from step (c) ranges from 1:100 to 1:

1.

33. The method of claim 31, wherein the compound of formula II is a compound of formula IIb and the compound of formula III is a compound of formula IIIa, and the molar ratio of the compound of formula IIb to the compound of formula IIIa in the microspheres from step (c) is in the range of 1:20 to 1:

8.

34. 21. A unit dosage container comprising a therapeutically effective amount of the pharmaceutical composition of any one of claims 2 to 20.

35. 35. The container of claim 34, wherein said compound of formula I is a compound of formula Ib.

36. 35. The container of claim 34, wherein said compound of formula II is a compound of formula IIb.

37. 35. The container of claim 34, wherein said compound of formula III is a compound of formula IIIa.

38. The container further contains a fluid, the fluid being selected from the group consisting of air, CO 2 , sulfur hexafluoride, C fluoride 1~6 35. The container of claim 34, wherein the solvent is an alkane, an alkane, or a combination thereof.

39. The fluoride C 1~6 39. The container of claim 38, wherein the alkane is selected from octafluoropropane, n-decafluorobutane, and dodecafluoropentane.

40. 40. The container of claim 39, wherein the fluid is n-decafluorobutane.

41. 35. The container of claim 34, wherein the composition further comprises a buffer, the buffer being a calcium- and magnesium-free phosphate solution.

42. 35. The container of claim 34, wherein the composition is capable of forming microspheres in the presence of water.

43. A kit comprising: At least one unit dosage container according to claim 34; instructions for using said kit; Including the kit.

44. 1. A method of reconstituting a microsphere, the method comprising: (a) adding a sufficient amount of water or saline solution to the microspheres in the container of claim 34; (b) optionally adding a volume of a fluid having a normal boiling point of less than 30° C. to the vessel of step (a); (c) shaking the container of step (a) or step (b); A method comprising:

45. 45. The method of claim 44, further comprising the step of filling the container with a gas prior to step (a).

46. 45. The method of claim 44, wherein the amount of water or saline solution is 500 milliliters or less.

47. 47. The method of claim 46, wherein the amount of water or saline solution added is sufficient to produce a homogenous mixture containing the reconstituted microspheres.

48. The method of claim 47, wherein the method further comprises step (c), and wherein the shaking of the container lasts for 180 seconds or less.

49. 10. A pharmaceutical composition according to claim 9 for use in a method for treating urolithiasis, the method comprising: administering to a subject having urolithiasis an effective amount of the pharmaceutical composition so that the microspheres come into contact with urinary stones; applying energy in a direction to the urinary stone in the subject at a frequency that excites fluid within the microsphere; A composition comprising:

50. 35. A container according to claim 34 for use in a method of treating urolithiasis, the method comprising: preparing reconstituted microspheres by adding a sufficient amount of water or saline solution to the container and shaking the container; administering an effective amount of the reconstituted microspheres to a subject so as to contact the microspheres with urinary stones; applying energy in a direction to the urinary stone in the subject at a frequency that excites fluid within the microsphere; 3. A container comprising:

Citation Information

Patent Citations

  • Calcium phosphate-binding liposome

    JP2009280500A

  • Targeting microbubbles

    US20130123781A1

  • Molecular imaging contrast agents and uses thereof

    WO2015134671A1

  • Bone-targeted gene carrier, preparation method therefor and application thereof

    WO2017197726A1